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Lysophosphatidic acid (LPA, 1- or 2-radyl-sn-glycerol 3-phosphate) is an 
important phospholipid, which elicits growth-factor-like effects in a number of cell types 
through cell surface G protein-coupled receptors (GPCRs). Extracellularly, the sole 
source of LPA is from the hydrolysis of lysophosphatidylcholine (LPC) by a secreted 
enzyme Autotaxin (ATX) through its lysophospholipase D activity. Due to exhibition of 
common features of the phosphodiesterase family, ATX was included as the second 
member of the nucleotide pyrophosphatase/phosphodiesterase (NPP) family. The 
emergence of ATX-LPA receptor axis has encouraged researchers to develop novel 
therapies for the prevention and treatment of cancer and other diseases.  
In order to study the precise physiological roles of each LPA receptors and ATX, 
I synthesized a set of LPA and LPC analogues as either ATX inhibitors or LPA receptor 
agonists/antagonists. Specific modifications in this thesis include optimization of the 
polar phosphonate head of LPA to phosphorothioate, restriction of glycerol backbone of 
LPA to phenyl ring and change of phosphonate head to vinyl sulfone in LPC molecule. 
All these analogues were tested in either in vitro or in vivo assays through external 
collaborations. One interesting result includes the identification of sn-2 radyl 
phosphorothioate analogues of LPA (sn-2 OMPT) as the most potent LPA5 receptor 
agonists. Furthermore, aromatic phosphonate analogues of LPA displayed very potent 
ATX inhibition. An in vivo study revealed that one of aromatic phosphonate analogues 
significantly reduced pulmonary fibrosis induced by bleomycin. In addition, 
fluorophosphonate and vinyl sulfone analogues of LPC were designed as activity-based 
probe (ABP) for selected enzymes of the NPP family. The study indicated that 
fluorophosphonate analogues cannot serve as ABP due to its high reactivity. In contrast, 
vinyl sulfone ABP analogues of LPC showed good inhibition of ATX. Meanwhile, the 
kinetics and dialysis suggested that vinyl sulfone analogues were irreversible inhibitors of 
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Numerous phospholipids found in nature display great diversity in the structures 
of both the apolar and the polar moieties of the lipid molecules. Phospholipids play 
multiple roles in cells other than as important structural elements of all biological cell 
membranes. For example, they were observed to have properties transporting 
cholesterol,1 resembling extracellular growth factors or signaling molecules.2,3 Multiple 
bioactive phospholipids, including lysobisphosphatidic acid (LBPA),1,4 lysophosphatidic 
acid (LPA),2,5 phosphatidic acid (PA),6,7 lysophosphatidylcholine (LPC),8-10 
sphingosylphosphorylcholine (SPC),11 and sphingosine 1-phosphate (S1P),12,13 have been 
the focus of intensive investigation in many research areas.14,15 
Lysophosphatidic acid (LPA) is one of the smallest and structurally simplest 
phospholipids known. LPA (1- or 2-acyl-sn-glycerol 3-phosphate) consists of a glycerol 
backbone with a fatty acyl chain either at the sn-1 position or at the sn-2 position, and a 
phosphate group at sn-3 position. (Figure 1.1) The saturated or unsaturated fatty acyl 
chains include palmitoyl (16:0), stearoyl (18:0), oleoyl (18:1), linoleoyl (18:2), linolenoyl 
(18:3), and so forth. 
  
 
Figure 1.1 Chemical structures of sn-1 and sn-2 LPA. 
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Although LPA is identified as an important bioactive lipid which induces alterations in 
blood pressure, smooth-muscle contraction, and platelet aggregation several decades ago, 
the significance and physiological implications of those early findings remain elusive 
until the late 1980s and early 1990s when LPA was shown to be an extracellular 
signaling molecule and its signaling pathway began to be identified. LPA signals by 
binding to specific receptors, which in turn leads to specific targeted cellular events. Cell 
surface LPARs belong to the membrane G protein-coupled receptor (GPCR) protein 
family. Both LPAR family members and autotaxin (ATX), a secreted enzyme converting 
LPC to LPA extracellularly, are aberrantly expressed in many human breast cancers and 
several other cancer lineages.16 In addition, a recent study revealed that ATX-LPARs axis 
plays an important role in breast tumorigenesis and cancer-related inflammation, which 
further validated that the ATX-LPAR axis as a critical therapeutic target in the cancer 
treatment.17 
 
1.2 Biosynthesis and Degradation of LPA 
LPA can be generated either extracellularly or intracellularly in response to 
various stimuli including growth factors, LPA itself, phorbol esters, and epidermal 
growth factor (EGF).18-20 A number of secreted and transmembrane ectoenzymes are 
responsible for the biosynthesis and metabolism of LPA.  
There are five possibilities for LPA production (Figure 1.2). First, LPA can be 
generated by esterification of glycerol-3-phosphate, which is catalyzed by glycerol 
phosphate acyltransferase (GPAT).21 Significant LPA produced in this route is converted 





Figure 1.2. LPA production and metabolism. 
 
 
role as a signaling molecule, but as a metabolic intermediate. These conversions occur in 
the endoplasmic reticulum. Hence, LPA from this route is not associated with the 
extracellular LPA signaling.22 
LPA also may be produced from phosphorylation of monoacylglycerol (MAG) 
catalyzed by monoacylglycerol kinase (MAGK). Spiegel et al. displayed data for a kinase 
that has an increased affinity for MAG and diacylglycerol (DAG) as substrates but not 
any other lipids tested including sphingosine and ceramide,23 which shows an example of 
the pathway from MAG to LPA. 
Similar to the GPAT pathway, LPA produced by MAGK could contribute to the 
intracellular LPA pool. Seiss and colleagues have demonstrated that LPA can be 
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generated from mild oxidation of low-density lipoprotein (LDL) in platelets and 
endothelial cells.  
Recent discovery indicated that extracellular LPA is mainly generated 
sequentially from phosphatidylcholine (PC) by phospholipase A (PLA) activities into 
LPC, then the phosphorus oxygen bond in membrane lysophosphatidylcholine can be 
cleaved to generate LPA catalyzed by the lysophospholipase D (lysoPLD) or ATX.24 
ATX is a tumor cell motility-stimulating factor, which belongs to a type II 
transmembrane ectoenzyme with multiple domains. The study suggests that the soluble 
form of ATX has the identical lysoPLD activity against LPC that can be determined in 
vitro by using mixed detergent and phospholipid micelles,24 which indicates that 
autocrine or paracrine production of LPA contributes to tumor cell motility, survival, and 
proliferation. The detailed ATX properties will be discussed in the following section.  
The last source of LPA is from hydrolysis of phosphatidic acid (PA) mediated by 
the phospholipase A1 (PLA1) or phospholipase A2 (PLA2). sn-2 LPA is formed by 
removal of acyl chain from sn-1 position by the PLA1 and sn-1 LPA formation is 
involved in the PLA2.25,26 This pathway is believed to be mainly intracellular or on the 
cell membrane since the substrate PAs are located in cell membranes.27 The latter two 
pathways of LPA production are likely to be biologically significant and occur outside 
the cell through ecto/exo-enzyme activity. 
The dominant metabolic pathway for terminating signaling by LPA is 
dephosphorylation to generate monoacylglycerol (MAG), a reaction which is catalyzed 
by a family of lipid phosphate phosphatases (LPPs) enzymes.28,29 There are four known 
isoforms in the LPP family, LPP1, LPP1a, LPP2, and LPP3, and LPP isoforms have 
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different substrate specificities. LPP1 and LPP3 have higher catalytic efficiency against 
PA compared with LPA, however LPP2 has higher activity against LPA than PA.30,31 
LPP is able to hydrolyze the extracellular LPA and other phospholipids, because the 
active domain for LPA dephosphorylation is located on the extracellular side of the 
plasma membrane. The second pathway for LPA degradation involves in the 
esterification of LPA to phosphatidic acid (PA) by the aid of lysophosphatidic acid 
acyltransferases (LPAAT). These enzymes catalyze the transport of an acyl chain from 
acyl-CoA to lysophospholipids (LPL) to from phospholipids. The last pathway for LPA 
degradation is the hydrolysis of the sn-1 acyl group to form the corresponding glycerol-3-
phosphate (G3P) by lysophospholipases (LPA-LPL). 
 
1.3 LPA Receptors and Signaling Pathways 
As mentioned previously, LPA-evoked responses are primarily mediated by cell 
surface G protein-coupled receptors (GPCRs). There are eight different LPA GPCRs thus 
far characterized on the surface of mammalian cells.32-38 LPA GPCRs have been 
identified in two distinct gene families. The first three were formerly called endothelial 
differentiation genes (EDG), EDG2/VZG-1/rec1.3, EDG4 (nonmutant) and EDG7. Due to 
the irregularity of the LPAR nomenclature, EDG2/VZG-1/rec1.3, EDG4(nonmutant) and 
EDG7 genes have been renamed LPA1, LPA2, and LPA3 respectively following the 
guidelines of the International Union of Basic and Clinical Pharmacology (IUPHAR). 
The LPARs in the EDG subfamily (LPA1-3) share 45-56% of their amino acids sequences. 
The overall homology of the transmembrane domains of LPA1-3 is 86%. However, there 
are only 6% of the amino acids conserved in their C-terminal tails. A second cluster of 
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LPA GPCR is related to purinergic receptor (P2Y) gene cluster.39 The previously 
identified P2Y9/GPR23/LPA4 and GPR92/LPA5 show about 35% amino acid similarity. 
More recently, there are additional related GPCRs, which appear to be activated by LPA. 
In chronological order based on the first publication include the GPR87 (human 
chromosomal location 3q25), P2Y5, and P2Y10 (human chromosomal location Xq21.1) 
gene products. G-protein independent LPA responses may also activated by the nuclear 
transcription factor peroxisome proliferators activated receptor γ (PPARγ).40 Through 
activation of these GPCRs and PPARγ, LPA plays an indispensable role in multiple 
physiological and pathological responses. These individual LPARs and their 
physiological and pathological functions will be introduced respectively. 
LPA1 was the first identified high affinity receptor for LPA.41 The mammalian 
(mouse and human) forms of LPA1 consist of 364 amino acids with 7 putative 
transmembrane domains.32 LPA1 is widely expressed in the adult mouse, particularly in 
brain, heart, lung, stomach, spleen, and skeletal muscle; interestingly, no expression is 
detectable in liver.42 The major locus of LPA1 expression is in the nervous system; there, 
it is spatially and temporally regulated throughout brain development.42,43 LPA1 couples 
with three types of G proteins, Gi/o, Gq, G12/13.44,45 LPA induces a range of cellular 
responses by binding with receptor LPA1: cell proliferation, serum-response element 
(SRE) activation, mitogen activated protein kinase (MAPK) activation, AC inhibition, 





Table 1.1. Summary of LPA GPCR receptors. 
Receptor G-protein 
coupling 








stress fiber formation, 
neurite retraction43,45 
Brian development, neuropathic 






Cell rounding45 Vascular injury64 
LPA3 
(EDG7) 
Gi/o, Gq/11 Neurite elongation45 Embryo implantation and 











Gq/11, G12/13 Stress fiber formation, 
neurite retraction, cell 
rounding52 
neuropathic pain and human 
platelet activation50,55 
GPR87 N/D Ca2+ mobilization56 N/D 
P2Y5 N/D CRE activation59 Hair growth59 
P2Y10 N/D Ca2+ mobilization62 N/D 






The second LPAR, LPA2, was identified from GenBank homology searches of 
orphan GPCR genes.46 LPA2 shares 60% amino acid similarity to that of LPA1. However, 
the tissue distribution of LPA2 is distinctly different from LPA1. LPA2 is extensively 
expressed in testes and peripheral blood leukocytes.32,46 Similar to LPA1, LPA2 regulates 
LPA-induced cellular signaling by coupling with three types of G proteins, Gi/o, Gq, G12/13, 
which is associated with intracellular Ca2+ mobilization, MAPK activation, and serum 
response element.46,47  
The last EDG family LPAR, LPA3, was identified through degenerate PCR 
strategies similar to those used to isolate LPA1.41 LPA3 shares approximately 50% amino 
acids similarity to human LPA1 and LPA2.47,48 The expression of LPA3 is observed in 
adult mouse testis, lung, kidney, small intestine, heart, brain, and thymus. In humans, it is 
found in the heart, pancreas, testis, lung, ovary, brain, and prostate.48 Unlike LPA1 and 
LPA2, LPA3 couples with Gi/o and Gq only.45 LPA3 is able to mediate pleiotropic LPA-
induced signaling that includes PLC activation, Ca2+ mobilization, AC 
inhibition/activation, and MAPK activation.45,47,48  
LPA4 (GPR23/P2Y9) is significantly different from EDG family receptors, which 
only shares 20-24% homology to LPA1-3. The LPA4 gene is highly expressed in the ovary 
and, to a much lesser extent, in the pancreas, thymus, and human kidney and skeletal 
muscle. Together with LPA5, LPA4 has been implicated in the inhibition of neurosphere 
formation and neuronal differentiation of human embryonic stem cells.49 LPA4 is 
involved in LPA-induced Ca2+ mobilization by binding to Gq and neurite retraction and 
stress fiber formation by binding to G12/13. The major difference of LPA4 from LPA1-3 is 
that it does not couple to the Gi/o protein. However, cAMP accumulation could be 
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induced by its binding with Gs. 
GPR92/LPA5 is widely expressed in murine tissues such as embryonic brain, 
small intestine, skin, spleen, stomach, thymus, lung, heart, liver, and embryonic stem 
cells.50 Its structural sequence is different from LPA1-3, sharing low sequence homology 
of 21-22%. On the contrary, it shares 31% amino acids identity with GPR23/LPA4.51 
LPA induces neurite retraction and stress fiber formation in LPA5-expressing cells by 
coupling to Gα12/13 and increases intracellular calcium levels by activation of Gαq.52 A 
recent study indicated that two other lipid-derived molecules, farnesyl pyrophosphate and 
narachidonylglycin, were characterized as LPA5 ligands.53 However, the further studies 
confirm that LPA5 is a bona fide LPAR which can also be activated by farnesyl 
pyrophosphate at much higher concentrations compared to LPA 18:1.54,55 The biological 
function of the agonistic activity of alternative ligands is unclear yet. The studies reveal 
LPA5 may play an important role in the response of neuropathic pain and human platelet 
activation.50,55  
The orphan GPCR GPR87 was deorphanized and shown to be a lysophosphatidic 
acid receptor in 2007.56 GPR87 shares a modest 27% and 25% homology with LPA4 and 
LPA5, respectively. However, GPR87 has ever been questioned as an LPAR. Although 
the expression of this receptor significantly enhanced LPA-induced Ca2+ mobilization in 
CHO cells, CHO cell line itself shows intrinsic response to LPA.57 A very recent study 
supports LPA as a ligand for GPR87 by using the TangoTM β–arrestin recruitment-based 
assay in U2OS cells.58 Further studies to characterize this receptor’s ligand selectivity 
and signal transduction properties are eagerly awaited. 
Human P2Y5 was originally reported as an orphan GPCR sharing the highest 
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sequence homology with GPR23/P2Y9/LPA4, which strongly indicated that LPA is a 
ligand for P2Y5.59 In a recent unbiased genetic search study, several mutations in the 
P2Y5 gene underlie autosomal recessive wooly hair. These studies clearly reveal that the 
involvement of human P2Y5 in the regulation of hair follicle development and hair 
growth and LPA signaling is involved in this pathway.59 However, the molecular 
mechanism that LPA-mediated hair follicle formation is still elusive. The comparison of 
the activation properties of P2Y5 by sn-1 and sn-2 LPA analogues suggests that sn-2-
substited LPA analogues are more potent and more efficacious than their corresponding 
sn-1 LPA analogues. In addition, the phosphorothioate analogues of LPA (OMPT), which 
were previously reported as LPA3-selective agonists, are more potent at the P2Y5 
receptor than LPA (18:1).60,61 Furthermore, the tissue expression of P2Y5 is not observed 
outside the skin and the hair. 
Fujita group’s study showed that sphingosine-1-phosphate (S1P) and LPA evoked 
intracellular Ca2+ increases in the CHO cells stably expressing the P2Y10 fused with a 
G16α protein.62 In the stable transfectants, LPA and S1P enhance Ca2+ transients with 
EC50 values of 53 nM and 130 nM, respectively.62 These Ca2+ responses are inhibited by 
S1P receptor and LPAR antagonists as well.62 Similar to GPR87, P2Y10 was questioned 
as an LPAR due to CHO cell used in Ca2+ response assay as well.57  
 The only identified intracellular receptor that binds LPA is located on the nuclear 
membrane and belongs to the peroxisome-proliferator-activated receptors (PPARs) 
family of nuclear receptors, which operated as heterodimers with retinoid X receptors to 
control the transcription of genes that contain specific peroxisome-proliferator-response 
elements (PPREs). There are three members of the PPAR family: PPARα, PPARβ, and 
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PPARγ. It has been proven that LPA is able to active PPARγ only.63 In this assay, the 
structure-activity profile of several fluorinated LPA analogues indicated that anionic 
phosphoryl group played a very important role in PPARγ activation. Although the 
position and nature of the acyl chain was not important for activation, PA shows no 
activity towards the nuclear receptor PPARγ.63 
 
1.4 ATX and Ectonucleotide Pyrophosphatase/Phosphodiesterase (NPP) 
ATX is a secreted protein of approximately 900 amino acids discovered by 
Liotta’s group in 1992.65 Due to exhibition of common features of the phosphodiesterase 
family, ATX was included as the second member of the nucleotide 
pyrophosphatase/phosphodiesterase (NPP) family.66 The NPP family consists of seven 
structurally related ecto-enzymes that numbered in chronological order. The relationship 
among members of the NPP family was concluded from homology sequence 
alignments.67 NPP1-3 share a very similar primary structure, including a short 
intracellular N-terminal region (10-80 residues), a single transmembrane domain (20 
residues) and a large extracellular C-terminal domain (about 800 residues).68 ENPP4-7 
are shorter proteins that contain a putative N-terminal signal peptide and a type I 
transmembrane domain in their C terminus.68 The substrates of NPPs include ATP, LPC, 
sphingomyelin and glycerophosphorylcholine etc. Interestingly, two distinct hydrolysis 
ways of ATP by by NPP1-3 have been identified. The products of hydrolysis are either 
AMP+PPi or ADP+Pi, respectively, depending on how ATP approaches the catalytic site. 
(Figure 1.3) LPC is nother example which can be hydrolyzed in two ways. (Figure 1.4) 

























































































Figure 1.4. The hydrolysis ways of LPC by ATX, NPP6 and NPP7. 
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extracellular lysophospholipase-D activity.24 Meanwhile, LPC also could be hydrolyzed 
into a MAG and choline phosphate by NPP6 and NPP7. 
Despite their fundamental importance, the reaction mechanism of phosphoesters 
or ATP hydrolysis by NPP is not fully understood yet. Similar to alkaline phosphatase 
(AP), a stepwise mechanism has been proposed for NPP hydrolysis.69,70 (Figure 1.5) First, 
nucleophilic attack by the metal-activated hydroxyl group of the catalytic-site threonine 
(or serine for NPP6) to the phosphate group of the incoming substrate results in the 



















































































Figure 1.5. Hydrolysis mechanism by mouse NPP1 from a homology model. 
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water molecule coordinated by the second metal attacks the phosphate, resulting in 
hydrolysis of the intermediate. Meanwhile, the catalytic site threonine/serine is 
regenerated and a phosphorylated product is released. The single catalytic site (Thr210 
for ATX) mediating both nucleotide pyrophosphatase and phosphodiesterase activities is 
critical for ATX’s lysoPLD activity as well.71 Although ATX shows phosphodiesterase, 
pyrophosphatase and ATPase activities, nucleotide and other model compounds are 
relativity poor substrates for ATX. 
 
1.5 ATX-LPA Receptor Axis in Cancer 
As discussed in Sections 1.3 and 1.4, the major source of extracellular LPA is 
generated sequentially from PC by phospholipase A activities into LPC, catalyzed by 
enigmatic ATX/lysoPLD ecto-phosphodiesterase.24 Normally, LPC is secreted by the 
liver and is significantly present in plasma, where it is predominantly bound to albumin 
and, to a lesser content, lipoproteins. LPC is also observed in the supernatant of cultured 
cells, which is presumably as a constituent of microvesicles that have been shed from the 
plasma membrane.72 Interestingly, microvesicle shedding has been implicated in the 
metastatic cascade, with malignant body fluids, like ascites, containing large amount of 
microvesicles, Therefore, bioactive LPA could be achieved from microvesicle-associated 
LPC, which would indicate an explanation for the connection between microvesicle 
shedding and metastasis.73 The identification of secreted ATX/lysoPLD as a tumor-
motility factor suggests a relationship between ATX/lysoPLD and cancers, and 
strengthens the evidence for a role which LPA plays in the initiation and progression of 
cancers.   
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In multiple cancer types, including ovarian and breast cancer, an abnormally high 
level of LPA production is observed. In addition, enhanced ATX and LPAR expression 
and decreased lipid phosphate phosphatase expression, which are highly correlated to 
LPA production, are discovered. In vitro, the effects of LPA on migration and invasion of 
ovarian cancer have been widely studied. The experiments indicate that LPA2 and LPA3 
are overexpresseed by a significant fraction of ovarian cancer cells, contributing to the 
feedback of ovarian cancer cells to LPA.74-76 Interestingly, LPA1 expression does not 
show a consistent change between normal and transformed epithelial ovarian cancer cells. 
Overexpression of LPA1 receptor in ovarian cancer cell lines induces apoptosis, which 
implicates that LPA1 may represent a negative regulator antagonizing positive signals 
delivered by other LPARs.74 Similar to ovarian cancer, breast cancer cells display 
abnormal expression of ATX, which promotes tumor aggressiveness.77 In addition, LPA 
and its receptors have recently been found to involve in prostate, colorectal, gastric, 
pancreatic and skin cancer.16 These studies strongly suggested that the abnormal 
regulation of ATX-LPA signaling is associated with ovarian and other cancers.     
ATX has been previously known to be a tumor cell motility-stimulating factor.78 
before the study revealed that ATX has extracellular lysophospholipase D activity which 
converts lysophosphatidylcholine (LPC) into lysophosphatidic acid (LPA).24 ATX may 
be the sole source of extracellular LPA, suggested by the experiment that ATX knockout 
mice led to lethality.79 Thus, in addition to a normal functional role in stabilizing blood 
vessels during embryonic development, local production of LPA by ATX/lysoPLD could 
support the invasion of tumor cells, promoting metastasis.73 The mechanisms of enhanced 
tumor cell invasion by LPA include two aspects. First of all, LPAR-mediated activation 
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of the Rho and Rac GTPase pathways are essential for the regulation of the actin 
cytoskeleton and cell motility.80 Second, LPA has been shown to regulate the activity of 
matrix metalloproteinases, which are also intimately involved in metastasis as well as in 
the LPA-induced transphosphorylation of the EGF receptor.81 Thus, ATX inhibitors may 
have potential in cancer therapy by blocking the growth-supporting and anti-apoptotic 
effects of LPA and decreasing its titer.82  
Previous studies have validated that LPA, ATX, LPARs, and lipid phosphate 
phosphatases play important role in cancer. Thus, there are multiple potential therapeutic 
targets in this pathway for the treatment of cancer and other diseases. In recent years, a 
considerable research effort from both the pharmaceutical industry and academic 
laboratories has led to many reports of novel LPAR antagonists, monoclonal antibodies 
binding to LPA and stabilized analogues of naturally occurring molecules or small 
molecules that inhibit ATX activity.83-93 
Since most biological functions mediated by LPA occur through GPCRs, LPAR 
antagonists become the direct and attractive targets for new anticancer agents (Figure 1.6). 
Currently, most known LPAR antagonists display dual or multiple receptor antagonism 
due to technical obstacle and similarities in receptor binding. DGPP (8:0) exhibits 
antagonist activity to LPA1 and LPA3, and the Ki values for LPA1 and LPA3 are 106 nM 
and 6.6 μM, respectively.83 VPC12249, in which a bulky hydrophobic group is attached, 
was discovered to be a dual LPA1/LPA3 antagonist.84 Furthermore, BrP-LPA is the first 
LPA4 receptor antagonist, which acts as both an ATX inhibitor (94% inhibition at 10 μM) 
and pan LPAR antagonist (LPA1: 1.5 μM, LPA2: 1.4 μM, LPA3: 1.2 μM, LPA4: 0.27 
μM).82 In 2008, Beck et al. discovered a potent LPA2 antagonist, and the Ki value for 
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LPA2 is 17 nM. Most importantly, this compound showed poor antagonistic activity (over 
50 μM) for LPA1/LPA3, which is the first antagonist specific to LPA2.85 
LPA and sphingosine-1-phosphate (S1P), which are the products of ATX-
catalyzed hydrolysis of its substrates LPC and sphingosyl-phosphorylcholine (SPC) 
respectively, were subsequently determined to show product feedback inhibition of ATX 
activity.86 A series of additional ATX inhibitors were discovered in recent year, including 
lysophosphatidic acid analogues,82 phosphatidic acid derivatives,87 darmstoff analogues88 




Figure 1.6. LPAR antagonists. 
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inhibitor of ATX, which was identified through high-throughput screening.90 These ATX 
inhibitors are all phospholipid analogues and share several common structural features, 
including a phosphate, thiophosphate or phosphonate polar head attached either with or 
without a linker to an alkyl or acyl chain. It is worth noting that several groups have made 
efforts to synthesize a few nonlipid ATX inhibitors, which indicated a new research 
direction for novel ATX inhibitor design91-93 (Figure 1.7). 
 
1.6 Rationale of Thesis Research 
As described above, ATX-LPARs have emerged as novel targets for the cancer 
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Figure 1.7. ATX inhibitors. 
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consists of over 40% drug targets in current clinical use. Meanwhile, LPA plays an 
important role in multiple physiological and pathological processes. Thus, the 
manipulation of specific effects engendered by LPA could have extensive applicability in 
novel drug design. In principle, both agonists and antagonists of LPARs have therapeutic 
potential. However, existing LPAR agonists, antagonists and ATX inhibitors, which 
prevent the production of LPA, are not satisfactory enough because of their relatively low 
potency, poor selectivity or bioavailability. To aid in identifying the role of ATX-LPARs 
further and validate ATX-LPARs as a target for cancer, additional stable, specific and  
potent LPAR agonists/antagonists and ATX inhibitors are needed. The objective of this 
thesis is to design a set of LPAR agonists/antagonists and ATX inhibitors. Furthermore, 
the biological functions were tested in vitro/in vivo. LPAR agonists/antagonists and ATX 
inhibitors designed in this thesis included the analogues of exsiting molecules and the 
mechanism-based inhibitors. The pharmacological studies of new compounds 
synthesized, combined with computer-aided modeling and ATX crystal structure, will be 
helpful for new drug discovery on LPA signaling pathway in the future. 
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Isoform-selective antagonists of the lysophosphatidic acid (LPA) G-protein 
coupled receptors (GPCRs) have important potential uses in cell biology and clinical 
applications. A novel phosphonothioate analogue (thio-ccPA 18:1) of carbacyclic 
phosphatidic acid (ccPA) was prepared by chemical synthesis. The pharmacological 
properties of thio-ccPA 18:1 were characterized for LPAR subtype-specific agonist and 
antagonist activity using Ca2+-mobilization assays in RH7777 cells expressing the 
individual EDG-family GPCRs. The study revealed that thio-ccPA 18:1 inhibited Ca2+ 
release through LPA1/LPA3 activation and was an LPA1/LPA3 antagonist. Meanwhile, 
thio-ccPA 18:1 showed an enhanced ability to inhibit ATX activity (89% at 10 μM). 
Furthermore, thio-ccPA 18:1 was selected to test the potential as melanoma therapeutic in 
vitro and as a probe of relative efficacy of inhibition of ATX, LPA1 and LPA3. Dr. Mandi 
Murph’s lab at the University of Georgia demonstrated that thio-ccPA 18:1 induced a 
marked reduction in the viability of B16F10 metastatic melanoma cells compared with 
PBS-treated control by 80-100%.  
 
2.2 Introduction 
The unique Physarum phospholipid PHYLPA, isolated from myxoamoebae of 
Physarum polycephalum, is an inhibitor of eukaryotic DNA polymerase.1 PHYLPA has a 
cyclopropane-containing fatty acyl chain and also consists of a cyclic phosphate at sn-2 
and sn-3 positions of the glycerol carbons.1,2 PHLYPA inhibits the proliferation of human 
fibroblasts cultured in a chemically defined medium.3 Although this compound is referred 
to as a cyclic phosphatidic acid (cPA) analogue, the absence of the second acyl group 
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makes it more accurately a cyclic form of lysophosphatidic acid (LPA). The biological 
activities of synthetic analogues of PHYLPA4 and the structure−activity relationships 
(SARs) indicated that the cyclic phosphate was required for antiproliferative activity.5 
The cellular effects elicited by cPA include antimitogenic regulation of the cell cycle,3,5,6 
regulation of actin stress fiber formation and rearrangement,6 inhibition of cancer cell 
invasion and metastasis,7 inhibition of platelet aggregation,8 regulation of differentiation 
and viability of neuronal cells, activation of Cl- currents,9 and mobilization of 
intracellular calcium.3 cPA is generated in blood and is bound to serum albumin.10 
Recently, a metabolically stabilized carbacyclic analogue of cPA, also known as ccPA, 
was described as a novel inhibitor of metastatic cancer (Figure 2.1).11,12 
In exploring a wide range of metabolically stabilized LPA analogues,13 we have 
identified the phosphorothioate14,15 as an important bioactive mimic of the phosphate. We 
thus envisaged the synthesis of the corresponding cyclic phosphonothioate analogue of 
thio-ccPA 18:1 (Figure 2.1). Since LPARs are responsible for cell proliferation and 
differentiation, cell migration, and cell invasion, we hypothesized that this ccPA analogue 
could be potential LPAR antagonist.16,17 Herein, we describe the synthesis of novel ccPA 




Figure 2.1. Cyclic phosphatidic acids and their carbacyclic analogues. 
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In addition, Dr. Mandi Murph’s lab also tested the potential of thio-ccPA 18:1 as 
a melanoma therapeutic in vitro and as a probe of relative efficacy of inhibition of ATX, 
LPA1 and LPA3. Although ATX inhibition contributes greatly to therapeutic efficacy 
against melanoma,20 the effect of thio-ccPA 18:1 on viability is not only related ATX 
inhibition since neither LPA nor a stabilized LPA analogue, R-OMPT21 that would 
bypass the inhibition of ATX, was able to override the inhibitory effects of thio-ccPA 
18:1.  
 
2.3 Chemical Synthesis 
In a previous synthesis,14,15 some unique chemical properties for 
phosphonothioate and phosphorothioate derivatives were observed. Several successful 
strategies to improve the synthetic efficiency have been carried out accordingly. For 
example, methyl and ethyl esters have often been used as protecting groups during 
syntheses of phosphatidic and phosphonatidic acids. However, deprotection with either 
trimethylsilyl iodide or trimethylsilyl bromide gave low yields of phosphonothioate or 
phosphorothioate derivatives.22 Hence, a convenient and versatile synthetic route to 
phosphonothioate ccPA was needed. Before the synthesis, we could not know which 
diastereomer would be active, herein, a racemic starting material expoxide 1 was used. 
Regiospecific ring opening of the commercially available benzyl glycidol ether with a 
carbon nucleophile, derived from dimethyl methylphosphonate in the presence of 
BF3·OEt2, furnished the corresponding racemic γ-hydroxy phosphonate 2.23 (Scheme 2.1) 
An intramolecular transesterification reaction of 4-(benzyloxy)-3-hydroxybutanephos- 
phonate to the corresponding cyclic compound 3 was achieved with pyridinium p- 
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Scheme 2.1.  Synthesis of the cyclic phosphonothioate.24 Reagents and conditions:  (a) 
LiCH2P(O)(OCH3)2, THF, BF3.Et2O, 100%; (b) PPTS, toluene, 44%; (c) 10% Pd/C, 1 
atm H2, 78%; (d) TBSCl, imidazole, DMF, 97%; (e) Lawesson's reagent, toluene, 67%; (f) 
TBAF·3H2O, HOAc, THF, 69%; (g) RCOOH, DCC/DMAP, dichloromethane, 77%; (h) 
t-BuNH2, 71% 
 
toluenesulfonate (PPTS) in toluene. With the cyclic intermediate in hand, it was 
important to conduct the hydrogenolysis of the benzyl protecting group prior to 
thionation of phosphonate. 
Thus, hydrogenolysis (Pd−C, 1 atm H2) proceeded readily at room temperature 
(rt). The primary alcohol 4 was protected as a tert-butyldimethylsilyl (TBS) ether 5, 
which can survive under thionation and yet still be removed under mild conditions. 
Introduction of the P=S group is the key transformation for the synthesis of 
phosphonothioates and phosphorothioates. We chose Lawesson's reagent for this 
transformation, as improved yields of thiophosphoryl products and milder reaction 
conditions were reported25 in comparison to P2S5.26 Thus, thionation of cyclic 
phosphonate 5 with Lawesson's reagent was accomplished by refluxing in toluene for 8 h 
to give the desired cyclic phosphonothioate 6 in good yield. The TBS ether 6 was then 
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removed with TBAF that had been neutralized with acetic acid, affording the primary 
alcohol 7. Esterification (DCC, DMAP, and either oleic acid, rt) was performed to give 
the racemic esters 8.  
Deprotection of the methyl ester from the cyclic phosphonothioate required a 
careful choice of reagent. While the commonly used electrophiles TMSBr or TMSI fail to 
deprotect phosphonothioates, tert-butylamine,27 trimethylamine,28 and lithium in liquid 
ammonia28 have been used for similar reactions. We chose tert-butylamine, because it 
was reported to remove methyl esters of either phosphonothioates or phosphorothioates 
under mild conditions. In the event, the charged phosphonothioate 9 was obtained as a 
diastereomer by refluxing the protected ester 8 in tert-butylamine for 3 days with 
moderate yield.  
 In order to support in vivo studies, a more efficient and robust synthetic route was 
required. Intermediate 2 was obtained by using the methodology we developed 
previously (Scheme 2.2). A base-induced intramolecular cyclization to give the 
phosphonate 3 was successfully performed by using sodium methoxide in THF. The yield 
of the cyclization was improved from 44% to 76% and more importantly, the purification 
of the final product 3 got easier compared to acid-promoted cyclization. Here, I want to 
emphasize that compound 3 consists of four possible structures (Figure 2.2), which is the 
mixture of four diastereomers. At the beginning, a racemic starting material was used; 
furthermore, the phosphorus atom itself is another chiral center. Two products were 
observed on TLC and we achieved both diastereomers. These two diastereomers showed 
similar 1H NMR but different 31P NMR. In order to keep the consistency with previous 
synthesis, I used the major product which showed the same NMR data of the product24  
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Scheme 2.2. Improved synthetic route for the cyclic phosphonothioate. (this work) 
Reagents and conditions:  (a) LiCH2P(O)(OCH3)2, THF, BF3.Et2O, 100%; (b) 1 eq 
NaOMe, THF, 67%; (c) 10% Pd/C, 1 atm H2, 78%; (d) RCOOH, DCC/DMAP, 































3 4  
Figure 2.2. Four possible diastereomers from the cyclization. 
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from previous synthesis for the following steps. In the previous route, we had to replace 
the benzyl protecting group with TBS to avoid the harsh conditions for removing benzyl 
group after the P=S bond was installed. In the new synthetic route, the ester formation 
was performed prior to thionation of phosphonate to give the compound 10. Use of 
Lawesson's reagent for the replacement of the oxo group of phosphorus (P=O) with the 
thio (P=S) was accomplished in refluxing toluene and such a conversion was 
sucusessfully achieved without affecting the carbonyl group.29 Then phosphonothioates 9 
were obtained as a mixture of diastereomers by removing methyl group of 8 in tert-
butylamine for 3 days. 
 
2.4 Biological Results 
The compound 9 was evaluated on the activation of LPARs designated (by 
convention) LPA1, LPA2, and LPA3 by Ca2+ mobilization in RH7777 cells expressing 
each individual human LPAR subtype. Table 2.1 illustrates calcium responses elicited 
through the activation of human LPA1, LPA2, and LPA3 receptors. In these experiments, 
RH7777 cells, which are intrinsically unresponsive to LPA, were transfected with human 
LPA1, LPA2, and LPA3, respectively.30,31  
While ccPA itself had no detectable LPAR agonist or antagonist effects, the thio-
ccPA was a LPA1/LPA3 selective antagonist, which showed partial LPA1 antagonist 
activity, blocking 64% of the response to 200 nM sn-1-oleoyl LPA. Importantly, the 
phosphonothioate ccPA analogues did not show any agonist-related activation of the 
three LPA GPCRs tested. Recent evidence shows that LPA is produced extracellularly 
from lysophosphatidylcholine by the lysophospholipase D activity of autotaxin identified 
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Table 2.1. Effects of Thio-ccPA 18:1 on RH7777 Cells Expressing LPA1-LPA3 and ATX 
inhibition.24 
 
 LPA1 LPA2 LPA3 ATX 
inhibition 
 
Compd. IC50 (nM) Ki (nM) IC50 (nM) Ki (nM) IC50 (nM) Ki (nM) 
 
 
ccPA NE NA  NE NA NE NA 
70% with 





941 ± 197 
 
403 ± 84.5 NE NA 1270 ± 160 636 ± 80 
 




as an autocrine motility factor for melanoma cells and has been implicated in tumor 
progression. The local production of LPA by ATX/lysoPLD could support an invasive 
microenvironment for tumor cells, exacerbating metastasis.19 Thus, LPAR antagonists 
and ATX inhibitors may have therapeutic potential in cancer therapy by blocking the 
growth-supporting and antiapoptotic effects of LPA and reducing its titer. The enhanced 
tumor cell invasion by LPA proceeds via two important molecular mechanisms. First, 
LPAR-mediated activation of the Rho and Rac GTPase pathways are essential for the 
regulation of the actin cytoskeleton and cell motility.32 Second, LPA has been shown to 
regulate the activity of matrix metalloproteinases, which are also intimately involved in 
metastasis as well as in the LPA-induced transphosphorylation of the epidermal growth 
factor (EGF) receptor.33  
Thio-ccPA 18:1 targets several components of the LPA signaling pathway. It is an 
effective inhibitor of ATX, similar to other cyclic phosphatidic acid analogues, but it also 
is a direct antagonist of the LPA1 and LPA3 receptors.34 A series of in vitro/in vivo 
studies conducted by Dr. Mandi Murph revealed that thio-ccPA 18:1 reduces viability in 
the highly aggressive B16F10 model for metastatic disease progression. In addition to 
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inhibiting the growth and viability of B16F10 melanoma cells in vitro, thio-ccPA inhibits 
two other commonly used human melanoma cell lines, A375 and MeWo as well. In the 
B16F10 metastatic melanoma mouse model, treatment with thio-ccPA 18:1 significantly 
reduced the number of pulmonary metastases in mice as compared to the control 
treatment. More importantly, metastatic lesions to organs outside of the lungs were 
effectively suppressive for thio-ccPA 18:1 treated mouse. These observations necessitate 
further exploration and exploitation of these targets in melanoma. 
 
2.5 Experimental Section 
General Procedures. Chemicals were obtained from Aldrich and Acros Chemical 
Corporation and were used without prior purification. Solvents used were of reagent 
grade and were distilled before use. Tetrahedronfuran was distilled from sodium wire, 
and methylene chloride was distilled from CaH2. Reactions were performed under an 
inert atmosphere (N2 or Ar) unless otherwise indicated. Flash chromatography (FC) 
employed Whatman 230−400 mesh ASTM silica gel. 1H and 13C spectra were recorded at 
400 MHz (1H), 101 MHz (13C), and 162 MHz (31P) at 25 °C. Chemical shifts are reported 
in ppm with TMS as internal standard for 13C and 1H (δ = 0.00); for 31P, 85% H3PO4 was 
assigned δ = 0.00.  
 
2.5.1 Dimethyl 4-(Benzyloxy)-3-hydroxybutanephosphonate (2)  
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A 2.5 M solution of n-BuLi (60 mL, 150 mmol) in Hex was added dropwise to a 
stirred solution of dimethyl methylphosphonate (18.6 g, 16.25 mL, 150 mmol) in dry 
tetrahedronfuran (150 mL) at −78 °C under a nitrogen atmosphere. After 15 min of 
stirring, a solution of the benzyl glycidol ether (8.21 g, 7.65 mL, 50 mmol) in 
tetrahedronfuran (25 mL) was added dropwise, followed by BF3·OEt2 (25.35 mL, 200 
mmol), which was slowly introduced, while maintaining the temperature below −70 °C. 
After stirring for 2 h, the reaction was quenched with saturated NH4Cl (150 mL) and was 
allowed to warm to room temperature. The residue obtained after concentration in vacuo 
was extracted with four portions of EtOAc (200 mL × 4). The organic extracts were 
washed with brine, dried with Na2SO4, and concentrated, and the residue was purified by 
FC (acetone/Hex:  1:1, Rf = 0.30) to yield 14.4 g of the pure hydroxy phosphonate ester 
(50 mmol, 100%). 1H NMR (CDCl3):  δ 7.30-7.22 (m, 5H), 4.48 (s, 2H), 4.34 (m, 1H), 
3.76 (d, J = 10.8 Hz, 6H), 3.39 (m, 2H), 2.23 (m, 1H), 2.09 (m, 1H), 1.96 (m, 1H), 1.85 
(m, 1H). 31P NMR (CDCl3):  δ 36.60 (s). MS (CI) m/z 289.1 (M++1, 100.00). HRMS, 
M++1, Found:  289.1211. Calcd for C13H22O5P, 289.1217.  
 
2.5.2 Methyl 3-Hydroxyl-4-benzyloxybutane 1,3-Cyclic  








To dimethyl 4-(benzyloxy)-3-hydroxybutanephosphonate (20.2 g, 70.18 mmol) 
dissolved in anhydrous toluene (450 mL) was added PPTS (pyridinium p-toluene 
 42
sulfonate, 34.0 g, 140 mmol). The mixture was heated to 80 °C for 20 h. After cooling to 
room temperature, H2O (200 mL) was added, and the mixture was extracted with EtOAc. 
The organic phase was dried with Na2SO4 and concentrated, and the residue was purified 
by FC (acetone/Hex:  1:1, Rf = 0.48) to yield the pure hydroxy phosphonate ester. (7.97 g, 
31.13 mmol, 44%). 1H NMR (CDCl3):  δ 7.33-7.26 (m, 5H), 4.57 (s, 2H), 4.34 (m, 1H), 
3.76 (d, J = 10.8 Hz, 3H), 3.56 (m, 2H), 2.23 (m, 1H), 2.09 (m, 1H), 1.96 (m, 1H), 1.85 
(m, 1H). 13C NMR (CDCl3):  δ 137.6 (s), 128.4 (s), 127.7 (s), 127.7 (s), 127.5 (s), 77.3 (d, 
J = 10.0 Hz), 73.5 (s), 72.1 (d, J = 6.1 Hz), 52.4 (d, J = 6.9 Hz), 25.8 (s), 18.3 (d, J = 
121.2 Hz). 31P NMR (CDCl3):  δ 51.04 (s). MS (CI) m/z 257.1 (M++1, 100.00). HRMS, 
M++1, Found:  257.0980. Calcd for C12H18O4P, 257.1017.  
 








A solution of 3 (2.1 g, 8.20 mmol) in absolute CH3OH (100 mL) containing 10% 
Pd−C catalyst (0.83 g) was stirred at ambient temperature under hydrogen (1 atm) until 
gas uptake ceased (18 h). Filtration and evaporation under reduced pressure gave 
compound 4, which was purified flash chromatography (acetone−Hex 2:1, Rf = 0.18) to 
give 1.06 g of homogeneous product (6.40 mmol, 78% yield).1H NMR (CDCl3):  δ 4.27 
(m, 1H), 3.68-3.76 (m, 2H), 3.72 (d, J = 12.0 Hz, 3H), 3.60 (m, 1H), 2.10−2.22 (m, 2H), 
2.00 (m, 1H), 1.80 (m, 1H). 13C NMR (CDCl3):  δ 79.3 (d, J = 10.0 Hz), 64.5 (d, J = 6.1 
Hz), 52.5 (d, J = 6.9 Hz), 24.9 (s), 18.5 (d, J = 120.7 Hz). 31P NMR (CDCl3):  δ 52.11 (s). 
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MS (CI) m/z 167.0 (M++1, 100.00). HRMS, M++1, Found:  167.0474. Calcd for 
C5H12O4P, 167.0475.  
 
2.5.4 Methyl 3-Hydroxyl-4-tert-Butyldimethylsilyloxybutane  
1,3-Cyclic Phosphonate (5)  
 
Alcohol 4 (0.420 g, 2.53 mmol) was dissolved in anhydrous DMF (10 mL) and 
stirred with imidazole (0.206 g, 3.04 mmol, 1.2 equiv) and TBSCl (0.420 g, 2.78 mmol, 
1.1 equiv) for 24 h at room temperature. The solution was diluted with water (5 mL) and 
EtOAc (20 mL), and the aqueous layer was separated and extracted with EtOAc (3 × 20 
mL). The combined organic layers were dried with Na2SO4 and concentrated in vacuo, 
and the residue was purified by FC (Hex−EtOAc 2:1, Rf = 0.40) to afford 0.392 g of the 
TBDMS ether 5 as a colorless liquid (1.40 mmol, 55%). 1H NMR (CD3Cl):  δ 4.22 (m, 
1H), 3.76-3.71 (m, 5H), 2.24-2.06 (m, 2H), 1.97-1.74 (m, 2H), 0.84 (s, 9H), 0.02 (m, 6H). 
13C NMR (CD3Cl):  δ 78.2 (d, J = 9.2 Hz), 67.2 (d, J = 6.1 Hz), 52.1 (d, J = 6.9 Hz), 25.6 
(s), 25.5 (d, J = 23.0 Hz), 18.7 (d, J = 122.7 Hz), 18.1 (s), −5.6 (s), −5.7 (s). 31P NMR 
(CDCl3):  δ 113.43 (s). MS (CI) m/z 281.2 (M++1, 100.00). HRMS, M++1, Found:  




2.5.5 Methyl 3-Hydroxyl-4-tert-butyldimethylsilyloxybutane  








A solution of 5 (0.553 g, 1.98 mmol) and Lawesson's Reagent (2,4-bis(p-
methoxyphenyl)-1,3-dithiadiphosphetane-2,4-disulfide) (0.44 g, 1.09 mmol) in toluene (3 
mL) was stirred and heated at reflux for 4 h. The reaction mixture was washed by water 
(3 mL) and extracted with toluene (3 × 3 mL). The combined extracts were dried over 
anhydrous Na2SO4 and filtered, the solvent was removed in a vacuum, and the residue 
was purified by FC (EtOAc:Hex, 1:10, Rf = 0.30) to give 0.39 g of 6 (1.320 mmol, 67% 
yield) as a colorless liquid.1H NMR (CD3Cl):  δ 4.37 (m, 1H), 3.67-3.71 (m, 5H), 2.12-
2.32 (m, 4H), 0.85 (s, 9H), -0.05 (s, 6H). 13C NMR (CD3Cl):  δ 81.5 (d, J = 3.9 Hz), 65.4 
(d, J = 6.8 Hz), 52.4 (d, J = 6.9 Hz), 29.2 (d, J = 84.5 Hz), 25.7 (s), -0.1 (s), -5.4 (s), -5.6 
(s). 31P NMR (CD3Cl):  δ 113.43 (s). MS (CI) m/z 297.1 (M++1, 100.00). HRMS, M++1, 
Found:  297.1128. Calcd for C11H26O3PSSi, 297.1146.  
 
2.5.6 Methyl 3,4-Dihydroxyl-butane 1,3-Cyclic  
Phosphonothioate (7)  
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A solution of 6 (143 mg, 0.48 mmol) in tetrahedronfuran (8 mL) was treated 
consecutively with acetic acid (83 μL, 1.45 mmol) and tetrabutylammonium fluoride 
trihydrate (457 mg, 1.45 mmol) at room temperature. After the solution was stirred for 18 
h, the reaction was complete (TLC). The solvent was then evaporated under reduced 
pressure, and the crude product was purified by FC on a short column (acetone:Hex, 3:2, 
Rf = 0.45) to afford 61 mg of a colorless liquid (0.33 mmol, 69% yield). 1H NMR 
(CD3Cl):  δ 4.30 (m, 1H), 3.55-3.76 (m, 5H), 2.92 (m, 1H), 2.02-2.31 (m, 5H). 13C NMR 
(CD3Cl):  δ 82.2 (d, J = 3.8 Hz), 64.5 (d, J = 6.1 Hz), 52.5 (d, J = 6.8 Hz), 29.5 (d, J = 
92.5 Hz), 25.4 (s). 31P NMR (CD3Cl):  δ 113.99 (s). MS (CI) m/z 183.0 (M++1, 100.00). 
HRMS, M++1, Found:  183.0245. Calcd for C5H12O3PS, 183.0246.  
 
2.5.7 Methyl 3-Hydroxyl-4-oleoyloxylbutane 1,3-Cyclic  
Phosphonothioate (8) 
 
To a solution of alcohol 7 (14 mg, 0.077 mmol) and oleic acid (24 mg, 0.133 
mmol) in dry dichloromethane (2 mL) at room temperature was added dropwise a 
solution of DCC (19 mg, 0.093 mmol) and DMAP (4 mg, 0.038 mmol) in dry 
dichloromethane (2 mL). The solution was stirred at room temperature for 16 h and 
filtered, the solvent was removed, and the residue was purified by FC (Hex−EtOAc 2:1, 
Rf = 0.40) to afford 26 mg (0.059 mmol, 77%) of 8 as a colorless liquid. 1H NMR 
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(CD3Cl):  δ 5.29 (m, 2H), 4.42 (m, 1H), 4.26 (m, 1H), 4.07 (m, 1H), 3.72 (d, J = 12.0 Hz, 
3H), 1.60-2.35 (m, 10H), 1.23-1.27 (m, 22H), 0.85 (t, J = 6.9 Hz, 3H). 13C NMR 
(CD3Cl):  δ 173.5 (s), 130.0 (s), 129.7 (s), 78.7 (d, J = 10.7 Hz), 65.4 (d, J = 6.9 Hz), 52.6 
(d, J = 6.9 Hz), 34.0 (s), 33.4 (s), 31.9 (s), 29.7 (s), 29.7 (s), 29.5 (s), 29.3 (s), 29.1 (s), 
29.1 (s), 27.2 (s), 27.1 (s), 25.7 (s), 24.8 (s), 22.7 (s), 19.1 (s), 17.9 (s), 14.1 (s). 31P NMR 
(CD3Cl):  δ 112.96 (s). MS (CI) m/z 447.1 (M+, 100.00). HRMS, M+, Found:  447.2632. 
Calcd for C23H43O4PS, 447.2648.  
 
2.5.8 3-Hydroxyl-4-oleoyloxylbutane 1,3-Cyclic  
Phosphonothioate (9)  
 
A solution of 8 (18 mg, 0.04 mmol) in 3 mL of tert-butylamine was refluxed for 
48 h. The excess tert-butylamine was removed by evaporation, and the resulting residue 
was purified by FC (dichloromethane:CH3OH:H2O, 8:1:0.05, Rf = 0.14). Further 
purification was performed by open column on Dowex 50WX8 100−200 (H+ form, 
CHCl3) and afforded 14 mg of a colorless liquid (0.03 mmol, 75% yield.) 1H NMR 
(CD3OD):  δ 5.34 (m, 2H), 4.44 (m, 1H), 4.20 (dd, J = 12.0, 3.2 Hz, 1H), 4.09 (dd, J = 
11.6, 6.0 Hz, 1H), 2.35 (t, J = 8.0 Hz, 2H), 2.10-2.20 (m, 2H), 2.02 (m, 4H), 1.61 (m, 2H), 
1.31 (m, 22H), 0.89 (t, J = 6.9 Hz, 3H). 13C NMR (CD3OD):  δ 173.2 (s), 128.9 (s), 128.8 
(s), 76.0 (s), 65.6 (s), 33.0 (s), 31.1 (s), 28.9 (s), 28.8 (s), 28.6 (s), 28.5 (s), 28.3 (s), 28.2 
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(s), 26.1 (s), 24.0 (s), 21.8 (s), 12.5 (s). 31P NMR (CD3OD):  δ 93.88 (s). MS (CI) m/z 
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AROMATIC PHOSPHONATE INHIBITORS OF 
THE LYSOPHOSPHOLIPASE D 
















Autotaxin (ATX) has emerged as an attractive target for the design of anti-
angiogenic and anti-invasive therapeutic agents. ATX is an extracellular 
lysophospholipase D that hydrolyzes lysophosphatidylcholine to form the bioactive lipid 
lysophosphatidic acid. S32826 is a phosphonate analogue that is a nanomolar inhibitor of 
ATX. S32826 features a tridecylamide substituent on aromatic ring, and its poor 
solubility and bioavailability severely limits its utility in vivo. cLogP calculations 
revealed the lipophilicity of S32826 could be lowered by shortening its hydrophobic 
chain and by introducing substituents alpha to the phosphonate. Herein, we described the 
syntheses and structure-activity relationships of a set of alpha-substituted phosphonate 
analogues of S32826 and their inhibition of ATX in vitro. Dr. Xiaoyu Xu in our lab 
further examined the use of these analogues to reduce migration of A549 lung carcinoma 
and MB-231 breast cancer cell lines in vitro. Interestingly, ATX potency is not predictive 
for inhibition of cell migration, indicating that simply reducing LPA availability is 
insufficient. The bioavailability plays an important role in the cell migration and other in 
vitro/in vivo assays. Meanwhile, the solubility of short chain phosphonate was improved 
compared to that of S32826. 
 
3.1 Introduction 
Autotaxin (ATX) also known as ectonucleotide pyrophosphatase/ 
phosphodiesterase 2 (NPP2 or ENPP2), is a secreted enzyme, which was initially thought 
to function exclusively as a phosphodiesterase/pyrophosphatas. Studies revealed that 
ATX had extracellular lysophospholipase D activity.1,2 In fact, the majority of biological 
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effects elicited by ATX can be explained by its lysophospholipase D activity that 
hydrolyzes lysophosphatidylcholine (LPC) to generate lysophosphatidic acid (LPA)  and 
choline.1,2 ATX may be the sole source of extracellular LPA and both LPC and LPA have 
been reported to stimulate migration through their respective G-protein coupled 
receptors.3 Thus, in addition to a normal functional role in stabilizing blood vessels 
during embryonic development, local production of LPA by ATX/lysoPLD could support 
the invasion of tumor cells, promoting metastasis.4 The mechanisms of enhanced tumor 
cell invasion by LPA include two aspects. First of all, LPAR-mediated activation of the 
Rho and Rac GTPase pathways are essential for the regulation of the actin cytoskeleton 
and cell motility.5 Second, LPA has been shown to regulate the activity of matrix 
metalloproteinases, which are also intimately involved in metastasis as well as in the 
LPA-induced transphosphorylation of the epidermal growth factor (EGF) receptor.6 Thus, 
ATX inhibitors may have potential in cancer therapy by blocking the growth-supporting 
and anti-apoptotic effects of LPA and decreasing its titer.7  
LPA and sphingosine-1-phosphate (S1P), which are the products of ATX-
catalyzed hydrolysis of its substrates LPC and sphingosyl phosphorylcholine (SPC) 
respectively, were subsequently determined to show product feedback inhibition of ATX 
activity.8 A series of additional ATX inhibitors were discovered in recent years, including 
lysophosphatidic acid analogues,7,9 phosphatidic acid derivatives,10 darmstoff analogues11 
and carba analogues of cyclic phsophatidic acid.12 These ATX inhibitors are all 
phospholipid analogues and share several common structural features, including a 
phosphate, thiophosphate or phosphonate polar head attached either with or without a 
linker to an alkyl or acyl chain. In a more recent study, the new type of nonlipid ATX 
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inhibitors was identified via virtual screen approach,13 which indicates a new research 
direction for novel ATX inhibitor design. S32826 was the first reported nanomolar 
inhibitor of ATX, and was identified through high-throughput screening14 (Figure 3.1). 
The polar head of S32826 is a metabolically-stabled phosphonate. The linker moiety of 
LPA is replaced by a phenyl ring in S32826, which restricts the flexibility of the linker 
compared to other LPA-analogue ATX inhibitors. In contrast to its high potency, the poor 
solubility of S32826 which could be related to the low membrane permeability capability 
due to its high lipophilicity limits the use in vivo. Low solubility can cause low 
bioavailability or give rise to large fluctuations in the fraction absorbed in humans that 
can often not be compensated by a high permeability. Furthermore, low solubility may be 
associated with stability problems and difficulties in developing an acceptable 
formulation.15 
Herein, a set of S32826 analogues have been synthesized and evaluated in in vitro 
assay. It is well-known that molecular size and lipophilicity are highly correlated and 
larger molecules generally display a higher clogP value than smaller ones. We believe 
that the solubility and membrane absorption could be improved for shorter acyl chain 
analogues. The structural features of various analogues synthesized in this paper are 
length of the fatty tail, lipophilicity and pKa of different polar heads.  
 
 
Figure 3.1. LPA and S32826. 
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3.3 Chemical Synthesis 
As illustrated in Scheme 3.1, the synthesis of the unsubstituted methylene 
phosphonate analogues 1a, 1b, 1c and 1d was completed in a three-step sequence. The 
acylation of commercially available phosphonate 5 proceeded smoothly and 
quantitatively to give the intermediate 6 by using acyl chloride in the presence of N, N-
diisopropylethylamine at 0 °C. The clean conversion was observed by TLC. A less polar 
spot came out and the starting material disappeared accordingly after 2 h reaction. 
Treatment of the monoacylated diethyl phosphate 6 with trimethylsilyl bromide (TMSBr) 
in methylene chloride followed by hydrolysis with aqueous CH3OH afforded the desired 
free acid. The final target compounds 1a, 2a and 3a were precipitated out as 
cyclohexylammonium salts from above solution by adding cyclohexlamine. Then the 
resulting salts were washed by the CH3OH to give the final products as white solids. The 
final products were characterized by 1H, 13C, 31P NMR and HRMS. The 31P spectrum of 
final product phosphonic acids displayed lower field signal (18.7 ppm) compared to their 
precursor phosphonates (26.4 ppm). 
Exploration of additional diversity at the polar head position of S32826 was 
enabled as described in Schemes 3.2 and 3.3. The -hydroxymethylene phosphonates are 
 
 
Scheme 3.1. Synthesis of methylene phosphonate analogues 1a, 2a, and 3a. Reagents and 
conditions: (a) RCOCl, DIPEA, dichloromethane, 2 h at 0 oC; (b) TMSBr, 
















































Scheme 3.2. Synthesis of α-hydroxymethylene phosphonate analogues 1b, 2b and 3b. 
Reagents and conditions: (a) diethyl phosphite, triethylamine, dichloromethane, overnight 
at rt; (b) Zn, NH4Cl, THF/EtOH/H2O;(c) RCOCl, DIPEA, dichloromethane, 2 h at 0 oC; 
(d) TMSBr, dichloromethane, overnight at rt; (e) CH3OH/H2O, 1 h at rt; (f) 
cyclohexylamine 
 
generally obtained by the Pudovik reaction,16 which involves the nucleophilic addition of 
a dialkyl phosphite to a carbonyl compound in the presence of base. As shown in 
Scheme 3.2, the aldehyde 7 was phosphorylated using a typical Pudovik procedure with 
diethyl phosphite and Et3N to give the -hydroxymethylene phosphonate 8 in good yield. 
The doublet of 1H NMR at 5.15 ppm verified the existence of α-hydroxymethylene. 
Hydrogenation reduction would fail to give correct product because α-hydroxyl group 
was sensitive to this condition. Instead, the reduction of nitro group was performed by 
using zinc dust and ammonium chloride in the mixture of tetrahydrofuran, ethanol and 
water at 80 oC for about 30 minutes to afford aniline 9 in excellent yield. The doublet of 
1H NMR at 4.86 ppm confirmed that α-hydroxyl group retained in the molecule and a 
more polar product spot was generated on TLC. The amides 10 and the 
cyclohexylammonium salts of compounds 1b, 2b, and 3b were prepared from aniline 9 in 
an analogous fashion described previously for their close analogue 1a.  
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Scheme 3.3 summarized the syntheses of α-halomethylene phoshponate analogues. 
Nucleophilic displacement of hydroxyl with diethylaminosulfur trifluoride (DAST) in 
anhydrous methylene chloride gave the corresponding monofluorinated compounds 11 in 
moderate yield.17 The 19F NMR spectrum of 1c, 2c and 3c had a doublet of doublet at -
198.0 ppm with coupling constants of 89.5 Hz and 44.7 Hz, which was split by the 
hydrogen and phosphorus, respectively, suggesting the existence of α-fluoro in the 
molecule. The -bromomethylene phosphonate 12 were thus prepared by the reaction of 
the corresponding -hydroxymethylene phosphonate with carbon tetrabromide and 
triphenylphosphine in methylene chloride. Then, the final targets 1c, 2c, 3c, and 1d were 
prepared from the phosphate by using the same protocol described previously. 
 
 
Scheme 3.3. Synthesis of α-halomethylene phosphonate analogues 1c, 2c, 3c and 1d. 
Reagents and conditions: (a) DAST, dichloromethane, 2 h at 0 oC then rt; (b) TMSBr, 
dichloromethane, overnight at rt; (c) CH3OH/H2O, 1 h at rt; (d) cyclohexylamine; (e) 






3.4 Biological Results 
The results reported in Table 3.1 indicate that the binding affinity for the ATX 
decreases with the reduction of acyl chain length. The C14:0 derivatives show the highest 
affinity. The standard compound 1a displays similar binding potency (9.0 nM) as what 
reported previously.14 Further optimization was attempted on changing the polar head 
from methylene phosphonate to α-substituted phosphonate. The α-fluoromethylene 
phosphonate analogue 1c is the most potent (6.1 nM) ATX inhibitor in this series and α-
bromomethylene phosphonate 1d showed very potent inhibitory activity (8.1 nM) as well. 
Most importantly, all three α-substituted phosphonate analogues 1b-1d display higher 
reduction (30 % at 10 μM) of cell migration of A549 and MB231 cells compared to 
compound 1a (15% at 10 μM) in scratch wound assay. The cLogP for all C14:0 
analogues are over 5.0, which are too high and correspond to their poor solubility. Most 
encouraging compounds are C10:0 derivatives. Methylene phosphonate analogue 2a and 
α-hydroxymethylene phosphonate analogue 2b exhibit just slightly lower binding affinity 
(18.0 nM and 24.2 nM). In contrast, the cLogP shows over 2 log units’ decrease which 
indicated that 2a and 2b showed improved solubility. The trend of water solubility was 
also observed when we made the solution of these compounds. The solubility of 2b in 
water is 4 mg/mL compared to 1 mg/mL for 1a. Meanwhile, compound 2b inhibits cell 
migration over 30% of A549 lung carcinoma and MB-231 breast cancer cell lines at 10 
μM. Moreover, all nonsubstituted compounds 1a, 2a, and 3a showed low efficacy 
compared to their according α-substituted compounds, which suggested the importance of 
α-substitution. Interestingly, compound 3c, a short chain α-fluoromethylene phosphonate 
analogue, showed weak inhibition of cell migration but 3a had no effect observed at 10  
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Table 3.1. Inhibition of autotaxin (ATX) phosphodiesterase activity by S32826 analogues. 
 







1a C13H27 H 9 (+) (+) 6.01 
1b C13H27 OH 24 (+++) (+++) 5.42 
1c C13H27 F 6.1 (+++) (++) 5.88 
1d C13H27 Br 8.1 (+++) (+++) 6.54 
2a C9H19 H 18 (±) NEd 3.9 
2b C9H19 OH 24.2 (+++) (+++) 3.31 
2c C9H19 F 72 (+) (+++) 3.77 
3a C6H13 H 512 NEd NEd 2.3 
3b C6H13 OH 1009 NT NT 1.72 
3c C6H13 F 834 (+) (+) 2.18 
 
a ATX inhibition assay was performed by Dr. Damian Madan at Echelon Biosciences Inc., 
Utah. 
b Inhibition of cell migration, scored as: (+++), ≥ 30% reduction at 10 μM; (++), ≥ 30% 
reduction at 30 μM; (+) , ≥ 15% reduction at 10 μM; (±), ≥ 15% reduction at 30 μM; NE, 
no effect observed at 30 μM; NT, not tested. Scratch wound-healing assay was carried 
out by Dr. Xiaoyu Xu in Dr. Prestwich’s Lab at the University of Utah. 
c cLogP was calculated by using ChemBioDraw Ultra11.0 






μM, although 3a displayed better binding affinity. Lastly, the compounds modified with 
the shortest acyl chain (7:0) showed the poor potency in the 0.5 μM and 1 μM range, 
which displayed low efficacy to reduce the cell migration accordingly. Hence, we 
conclude there is a balance between the chain length and efficacy. 
In summary, we developed a set of S32826 analogues. ATX inhibitory activity 
and cell migration was determined for these compounds. In contrast to the poor solubility 
and low efficacy to reduce cell migration of 1a, α-hydroxymethylene phosphonate 
analogue (C10:0) was identified as the potential target, which displayed good potency, 
better solubility and the higher reduction of cell migration. Further studies for this 
compound currently are ongoing. 
 
3.5 Experimental Procedures 
All chemicals and solvents were purchased from Aldrich, Alfa Aesar or Acros 
Chemical Corporation and used without prior purification. Thin-layer chromatography 
was performed on pre-coated silica gel aluminum sheets (EM SCIENCE silica gel 60F254). 
Purification of compounds was carried out by normal phase chromatography (ISCO 
[Combiflash], Silica gel 230~400 mesh). NMR spectra were recorded using a Varian 
Mercury 400 at 400 MHz (1H), 101 MHz (13C), 162 MHz (31P), 376 MHz (19F) at 25oC. 
Chemical shifts are given in ppm with TMS as internal standard (δ=0.00); 31P, 85% 
H3PO4 (δ=0.00). NMR peaks were assigned by MestRe-C (4.9.9.9). Low and high-
resolution mass spectra were obtained on HP5971A MSD and Finnigan MAT95 double 




3.5.1 General procedure for acylation of aniline 
To a solution of diethyl (4-aminophenyl)(hydroxy)methylphosphonate 9 (1.0 g, 
3.84 mmol, 1.0 equiv.) in dry methylene chloride (50 mL) at 0 ºC was added myristoyl 
chloride (1.24 mL, 4.62 mmol, 1.2 equiv.) followed by N,N-diisopropylethylamine (1.39 
mL, 8.45 mmol, 2.2 equiv.). The above mixture was stirred at 0 ºC for 1 h, then room 
temperature 1 h before poured into saturated NaHCO3 (60 mL). The water layer was 
extracted by methylene chloride (100 mL) twice. All organic layers were combined, dried 
over Na2SO4, then concentrated to get a white solid, which was purified on ISCO (80g 
SiO2, EtOAc in Hex, 70% - 100%) to give a white solid 10a (833 mg, 88%). 
 












Rf  0.11 (Hex/EtOAc = 1/1); 1H NMR (CDCl3) δ 7.70 (s, 1H), 7.43 (d, J = 8.0 Hz, 
2H), 7.18 (dd, J = 8.4, 2.0 Hz, 2H), 3.93-4.04 (m, 4H), 3.08 (d, J = 21.6 Hz, 2H), 2.33 (t, 
J = 7.6 Hz, 2H), 1.64-1.74 (m, 2H), 1.26-1.39 (m, 6H), 1.23 (t, J = 6.8 Hz, 6H), 0.87 (t, J 
= 7.2 Hz, 3H); 13C NMR (CDCl3) δ 171.5 (s), 137.2 (s), 130.2 (s), 130.2 (s), 126.8 (s), 
126.7 (s), 119.9 (s), 62.2 (s), 62.1 (s), 37.7 (s), 33.8 (s), 32.4 (s), 31.6 (s), 29.0 (s), 25.6 
(s), 22.5 (s), 16.4(s), 16.3 (s), 14.0 (s); 31P NMR (CDCl3) δ 26.4 (1P); MS (ESI) m/z 
















Rf  0.14 (Hex/ EtOAc = 1/1); 1H NMR (CDCl3) δ 7.54 (s, 1H), 7.44 (d, J = 8.4 Hz, 
2H), 7.19 (dd, J = 8.4, 2.4 Hz, 2H), 3.93-4.04 (m, 4H), 3.08 (d, J = 21.2 Hz, 2H), 2.33 (t, 
J = 7.6 Hz, 2H), 1.64-1.74 (m, 2H), 1.18-1.39 (m, 18H), 0.86 (t, J = 7.2 Hz, 3H); 13C 
NMR (CDCl3) δ 171.4 (s), 137.0 (s), 130.3 (s), 130.2 (s), 126.9 (s), 119.9 (s), 119.8 (s), 
62.2 (s), 62.1 (s), 37.8 (s), 33.8 (s), 32.4 (s), 31.8 (s), 29.4 (s), 29.4 (s), 29.3 (s), 29.2 (s), 
22.6 (s), 16.4 (s), 16.3 (s), 14.1 (s); 31P NMR (CDCl3) δ 26.4 (1P); MS (ESI) m/z 398.4 
(M++1); HRMS for C21H37NO4P (M++1): found 398.2459, calcd 397.2460. 
 
3.5.4 Diethyl 4-tetradecanamidobenzylphosphonate (6a) 
 
Rf  0.18 (Hex/EtOAc = 1/1), 1H NMR (CDCl3) δ 7.67 (s, 1H), 7.43 (d, J = 8.4 Hz, 
2H), 7.18 (dd, J = 8.4, 2.0 Hz, 2H), 3.93-4.04 (m, 4H), 3.08 (d, J = 21.6 Hz, 2H), 2.33 (t, 
J = 7.6 Hz, 2H), 1.64-1.74 (m, 2H), 1.18-1.39 (m, 26H), 0.87 (t, J = 7.2 Hz, 3H); 13C 
NMR (CDCl3) δ 171.5 (s), 137.1 (s), 130.2 (s), 130.2 (s), 126.8 (s), 119.8 (s), 119.8 (s), 
62.2 (s), 62.1 (s), 37.7 (s), 33.8 (s), 32.4 (s), 31.9 (s), 29.6 (s), 29.6 (s), 29.6 (s), 29.5 (s), 
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29.4 (s), 29.3 (s), 25.6 (s), 22.7 (s), 16.4 (s), 16.3 (s), 14.1 (s); 31P NMR (CDCl3) δ 26.4 
(1P); MS (ESI) m/z 454.5 (M++1); HRMS for C25H45NO4P (M+): found 454.3082, calcd 
454.3086. 
 
3.5.5 4-Heptanamidobenzylphosphonic acid (3a) 
 
1H NMR (CD3OD) δ 7.40 (d, J = 8.4 Hz, 2H), 7.27 (dd, J = 8.8, 2.4 Hz, 2H), 
2.92-3.02 (m, 1H), 2.91 (d, J = 20.8 Hz, 2H), 2.33 (t, J = 7.2 Hz, 2H), 1.92-1.99 (m, 2H), 
1.78-1.84 (m, 2H), 1.63-1.72 (m, 4H), 1.18-1.41 (m, 10H), 0.91 (t, J = 6.8 Hz, 3H); 13C 
NMR (CD3OD) δ 179.9 (s), 129.6 (d), 119.6 (s), 50.1 (s), 36.6 (s), 35.3 (s), 31.2 (d), 28.6 
(s), 26.4 (s), 25.5 (s), 24.6 (s), 24.0 (s), 22.2 (s), 12.9 (s); 31P NMR (CD3OD) δ 18.7 (1P); 
MS (ESI) m/z 300.3 (M++1); HRMS for C14H24NO4P (M++1): found 300.1360, calcd 
300.1365. 
 




1H NMR (CD3OD) δ 7.40 (d, J = 8.0 Hz, 2H), 7.27 (dd, J = 8.8, 2.0 Hz, 2H), 
2.95-3.02 (m, 1H), 2.91 (d, J = 20.4 Hz, 2H), 2.33 (t, J = 7.6 Hz, 2H), 1.92-2.00 (m, 2H), 
1.79-1.86 (m, 2H), 1.63-1.72 (m, 4H), 1.18-1.41 (m, 16H), 0.91 (t, J = 6.8 Hz, 3H); 13C 
NMR (CD3OD) δ 173.1 (d), 129.6 (d), 119.6 (s), 49.1 (d), 46.9 (s), 36.6 (s), 29.2 (m), 
25.6 (s), 24.5 (s), 23.9 (s), 22.3 (s), 19.2 (s), 13.0 (s); 31P NMR (CD3OD) δ 18.7 (1P); MS 
(ESI) m/z 342.3 (M++1); HRMS for C17H29NO4P (M++1): found 342.1830, calcd 
342.1834. 
 
3.5.7 4-Tetradecanamidobenzylphosphonic acid (1a) 
 
1H NMR (CD3OD) δ 7.40 (d, J = 8.0 Hz, 2H), 7.27 (dd, J = 8.8, 2.0 Hz, 2H), 
3.00-3.06 (m, 1H), 2.93 (d, J = 20.4 Hz, 2H), 2.33 (t, J = 7.6 Hz, 2H), 1.95-2.01 (m, 2H), 
1.80-1.86 (m, 2H), 1.63-1.72 (m, 4H), 1.18-1.41 (m, 24H), 0.91 (t, J = 6.8 Hz, 3H); 13C 
NMR (CD3OD) δ 171.9 (s), 129.6 (d), 50.1 (s), 119.6 (s), 36.6 (s), 31.6 (s), 29.2 (s), 29.0 
(d), 28.9 (s), 25.6 (s), 24.5 (s), 23.9 (s), 22.3 (s), 13.0 (s); 31P NMR (CD3OD) δ 18.7 (1P); 
MS (ESI) m/z 398.4 (M++1); HRMS for C21H37NO4P (M++1): found 398.2454, calcd 
398.2460. 
To a solution of 4-nitrobenzaldehyde 7 (14.0 g, 92.7 mmol, 1.0 equiv.) in dry 
methylene chloride (400 mL) was added diethyl phosphite (19.2 g, 139 mmol, 1.5 equiv.) 
followed by N,N-diisopropylethylamine (23.1 mL, 139 mmol, 1.5 equiv.). The above 
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mixture was stirred at room temperature overnight. Then the reaction mixture was 
concentrated and purified on ISCO (330g SiO2, EtOAc in Hex, 40% - 70%) to give a 
clear oil 8 (22.8 g, 85%). 
 










Rf  0.15 (Hex/ EtOAc = 1/1); 1H NMR (CDCl3) δ 8.18 (d, J = 8.0 Hz, 2H), 7.64 
(dd, J = 8.4, 2.0 Hz, 2H), 5.15 (d, J = 12.4 Hz, 1H), 4.02-4.14 (m, 4H), 1.20-1.28 (m, 6H); 
13C NMR (CDCl3) δ 147.4 (d), 144.5 (d), 127.7 (d), 123.2 (d), 130.2 (s), 70.8 (s), 69.2 (s), 
64.0 (d), 63.2 (d), 16.3 (m); 31P NMR (CDCl3) δ 19.7 (1P); MS (ESI) m/z 290.2 (M++1); 
HRMS for C11H17NO6P (M++1): found 290.0787, calcd 290.0793. 
To a solution of diethyl hydroxy(4-nitrophenyl)methylphosphonate 8 (1.0 g, 3.45 
mmol, 1.0 equiv.) in tetrahedronfuran/ethanol/water (30 mL/7.5 mL/3.0 mL) was added 
Zinc dust (2.24 g, 34.5 mmol, 10.0 equiv.) and ammonium chloride (925 mg, 17.3 mmol, 
5.0 equiv.). The above mixture was stirred at 80 oC about 30 min under nitrogen. TLC 
showed all starting materials were consumed. Then the reaction mixture was filtered out 
through Celite and the cake was washed by EtOAc. The organic mixture was 
concentrated and purified on ISCO (40g SiO2, EtOAc in Hex, 80% - 100%) to give a 














Rf  0.10 (EtOAc); 1H NMR (CDCl3) δ 7.21-7.27 (m, 2H), 6.65 (d, J = 1.6 Hz, 2H), 
4.86 (d, J = 8.8 Hz, 1H), 3.75-4.10 (m, 4H), 1.25 (t, J = 6.8 Hz, 3H), 1.19 (t, J = 6.8 Hz, 
3H); 13C NMR (CDCl3) δ 146.9 (d), 128.4 (d), 126.5 (s), 115.4 (s), 71.3 (s), 69.7 (s), 63.2 
(m), 16.4 (m); 31P NMR (CDCl3) δ 21.9 (1P); MS (ESI) m/z 282.2 (M+Na+); HRMS for 
C11H19NO6P (M++1): found 260.1057, calcd 260.1052. 
 














1H NMR (CDCl3) δ 8.17 (s, 1H), 7.43 (d, J = 8.4 Hz, 2H), 7.27-7.32 (m, 2H), 4.92 
(d, J = 11.6 Hz, 1H), 3.86-4.10 (m, 4H), 2.36 (t, J = 7.6 Hz, 2H), 1.62-1.75 (m, 2H), 1.15-
1.40 (m, 12H), 0.88 (t, J = 6.8 Hz, 3H); 13C NMR (CDCl3) δ 172.0 (s), 138.2 (d), 131.8 
(s), 127.6 (d), 119.8 (s), 71.3 (s), 69.7 (s), 63.3 (m), 37.6 (s), 31.6 (s), 29.0 (s), 25.6 (s), 
22.5 (s), 16.3 (m), 14.0 (s); 31P NMR (CDCl3) δ 21.3 (1P); MS (ESI) m/z 394.2 (M+Na+); 
HRMS for C18H31NO5P (M++1): found 372.1934, calcd 371.1940. 
  
68














1H NMR (CDCl3) δ 8.33 (s, 1H), 7.41 (d, J = 8.4 Hz, 2H), 7.27-7.32 (m, 2H), 4.90 
(d, J = 11.6 Hz, 1H), 3.86-4.10 (m, 4H), 2.35 (t, J = 7.6 Hz, 2H), 1.62-1.75 (m, 2H), 1.15-
1.40 (m, 18H), 0.87 (t, J = 6.8 Hz, 3H); 13C NMR (CDCl3) δ 172.2 (s), 138.3 (d), 131.8 
(s), 127.6 (d), 119.9 (s), 71.3 (s), 69.7 (s), 63.3 (m), 37.5 (s), 31.8 (s), 29.4 (m), 25.6 (s), 
22.6 (s), 16.3 (m), 14.0 (s); 31P NMR (CDCl3) δ 21.2 (1P); MS (ESI) m/z 436.4 (M+Na+); 
HRMS for C21H37NO5P (M++1): found 414.2407, calcd 413.2409. 
 














1H NMR (CDCl3) δ 8.14 (s, 1H), 7.41-7.46 (m, 2H), 7.29-7.35 (m, 2H), 4.92 (d, J 
= 12.0 Hz, 1H), 3.86-4.10 (m, 4H), 2.35 (t, J = 7.6 Hz, 2H), 1.64-1.77 (m, 2H), 1.20-1.45 
(m, 26H), 0.87 (t, J = 6.8 Hz, 3H); 13C NMR (CDCl3) δ 172.0 (s), 138.3 (s), 131.8 (s), 
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130.0 (s), 127.7 (s), 119.8 (s), 71.3 (s), 69.7 (s), 63.2 (m), 37.6 (s), 31.9 (s), 29.8 (s), 29.7 
(s), 29.5 (s), 29.4 (s), 29.3 (s), 29.2 (s), 27.2 (d), 25.6 (s), 22.7 (s), 16.5 (s), 16.4 (s), 16.3 
(s), 14.1 (s); 31P NMR (CDCl3) δ 21.4 (1P); MS (ESI) m/z 453.4 (M++1-OH); HRMS for 
C25H45NO5P (M++1): found 470.3026, calcd 470.3035. 
 
3.5.13 Sodium hydrogen(4-heptanamidophenyl)(hydroxy) 
methylphosphonate (3b) 
 
1H NMR (CD3OD) δ 7.41-7.48 (m, 4H), 4.70 (d, J = 12.4 Hz, 1H), 2.34 (t, J = 7.6 
Hz, 2H), 1.33-1.35 (m, 2H), 1.25-1.41 (m, 6H), 0.91 (t, J = 6.8 Hz, 3H); 13C NMR 
(CD3OD) δ 173.1 (s), 127.4(d), 119.1 (s), 46.9 (s), 36.6 (s), 31.3 (s), 28.6 (s), 25.6 (s), 
22.2 (s), 12.9 (s); 31P NMR (CD3OD) δ 15.8 (1P); MS (ESI) m/z 338.12 (M+1+); HRMS 
for C14H23NO5P (M++1): found 317.1386, calcd 317.1392. 
 
3.5.14 (4-Decanamidophenyl)(hydroxy)methyl 




1H NMR (CDCl3) δ 7.45-7.48 (m, 4H), 4.71 (d, J = 12.4 Hz, 1H), 2.95-3.05 (m, 
1H), 2.34 (t, J = 7.6 Hz, 2H), 1.92-2.00 (m, 2H), 1.79-1.85 (m, 2H), 1.61-1.72 (m, 4H), 
1.23-1.41 (m, 19H), 0.89 (t, J = 6.8 Hz, 3H); 13C NMR (CDCl3) δ 173.2 (s), 127.5 (d), 
119.2 (s), 50.1 (s), 36.6 (s), 31.6 (s), 30.5 (s), 29.0 (m), 25.6 (s), 24.5 (s), 23.9 (s), 22.3 (s), 
13.0 (s); 31P NMR (CDCl3) δ 16.1 (1P); MS (ESI) m/z 380.2 (M+Na+); HRMS for 
C17H29NO5P (M++1): found 258.1790, calcd 358.1783. 
 
3.5.15 Hydroxy(4-tetradecanamidophenyl)methyl 
phosphonic acid (1b) 
 
To a solution of diethyl (4-aminophenyl)(hydroxy)methylphosphonate 10c (1.1 g, 
3.5 mmol, 1.0 equiv.) in dry dicloromethane (30 mL) at 0 ºC was added 
diethylaminosulfur trifluoride (1.74 mL, 7.0 mmol, 2.0 equiv.) slowly under nitrogen. 
The above mixture was stirred at 0 ºC for 2 h before quenched by saturated NaHCO3 
(60mL). The water layer was extracted by dicloromethane (100 mL) twice. All organic 
layers was combined, dried over Na2SO4, then concentrated to get a yellow oil, which 
was purified on ISCO (40g SiO2, EtOAc in Hex, 30% - 60%) to give compound 11c as a 



















1H NMR (CDCl3) δ 8.42 (s, 1H), 7.54 (d, J = 8.4 Hz, 2H), 7.34 (d, J = 8.4 Hz, 
2H), 5.54 (dd, J = 44.4, 6.8 Hz, 1H), 3.95-4.17 (m, 4H), 2.36 (d, J = 7.6 Hz, 2H), 1.66-
1.74 (m, 2H), 1.23-1.37 (m, 12H), 0.87 (t, J = 6.8 Hz, 3H); 13C NMR (CDCl3) δ 172.1 (s), 
139.7 (s), 127.7 (s), 119.6 (s), 90.9 (s), 89.2 (s), 89.0 (s), 87.3 (s), 63.5 (m), 37.6 (s), 31.5 
(s), 25.5 (s), 22.5 (s), 16.3 (m), 14.0 (s); 31P NMR (CDCl3) δ 14.9 (d, J = 89.3 Hz, 1P); 
19F NMR (CDCl3) δ 198.14 (dd, J = 89.5, 44.7 Hz, 1F); MS (ESI) m/z 396.3 (M+Na+); 
HRMS for C18H30FNO4P (M++1): found 374.1884, calcd 374.1896. 
 














1H NMR (CDCl3) δ 7.74 (s, 1H), 7.54 (d, J = 8.4 Hz, 2H), 7.39 (d, J = 8.8 Hz, 
2H), 5.52 (dd, J = 44.4, 7.2 Hz, 1H), 3.95-4.10 (m, 4H), 2.36 (d, J = 7.6 Hz, 2H), 1.66-
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1.74 (m, 2H), 1.23-1.37 (m, 18H), 0.87 (t, J = 6.8 Hz, 3H); 13C NMR (CDCl3) δ 171.7 (s), 
139.2 (d), 127.8 (m), 119.4 (s), 63.5 (m), 37.7 (s), 31.8 (s), 29.3 (m), 25.5 (s), 22.6 (s), 
16.4 (m), 14.0 (s); 31P NMR (CDCl3) δ 14.9 (d, J = 89.3 Hz, 1P); 19F NMR (CDCl3) δ 
198.14 (dd, J = 89.5, 44.7 Hz, 1F); MS (ESI) m/z 437.28 (M+Na+); HRMS for 
C21H36FNO4P (M++1): found 416.2371, calcd 416.2366. 
 














1H NMR (CDCl3) δ 9.29 (s, 1H), 7.50 (d, J = 8.4 Hz, 2H), 7.23 (d, J = 8.0 Hz, 
2H), 5.54 (dd, J = 44.0, 7.2 Hz, 1H), 3.87-4.08 (m, 4H), 2.29 (d, J = 7.2 Hz, 2H), 1.55-
1.65 (m, 2H), 1.12-1.25 (m, 26H), 0.78 (t, J = 6.8 Hz, 3H); 13C NMR (CDCl3) δ 172.6 (s), 
140.0 (s), 127.6 (s), 126.9 (s), 119.6 (s), 63.7 (d), 63.4 (d), 37.2 (s), 31.8 (s), 29.6 (s), 29.5 
(s), 29.4 (s), 29.3 (s), 25.6 (s), 16.4 (s), 16.3 (s); 31P NMR (CDCl3) δ 14.9 (d, J = 90.0 Hz, 
1P); 19F NMR (CDCl3) δ 197.12 (dd, J = 90.0, 44.0 Hz, 1F); MS (ESI) m/z 472.7 (M++1); 





















1H NMR (CD3OD) δ 7.43-7.48 (m, 4H), 4.71 (d, J = 12.4 Hz, 1H), 2.34 (t, J = 7.6 
Hz, 2H), 1.61-1.71 (m, 2H), 1.28-1.41 (m, 6H), 0.91 (t, J = 6.8 Hz, 3H); 13C NMR 
(CD3OD) δ 173.1 (s), 127.4(d), 119.1 (s), 36.6 (s), 31.3 (s), 28.6 (s), 25.6 (s), 22.2 (s), 
12.9 (s); 31P NMR (CD3OD) δ 10.2 (d, J = 81.1 Hz, 1P); 19F NMR (CD3OD) δ 195.30 (dd, 
J = 78.2, 45.5 Hz, 1F); MS (ESI) m/z 396.3 (M+Na+); HRMS for C14H21NO4P (M++1-
HF): found 298.1198, calcd 298.1208. 
 
3.5.20 (4-Decanamidophenyl)fluoromethylphosphonic acid (3b) 
 
1H NMR (CD3OD) δ 7.38-7.54 (m, 4H), 5.45 (dd, J = 45.2, 8.0 Hz, 1H), 2.86-
2.94 (m, 1H), 2.35 (d, J = 7.6 Hz, 2H), 1.85-1.98 (m, 2H), 1.75-1.83 (m, 2H), 1.63-1.73 
(m, 4H), 1.12-1.25 (m, 16H), 0.89 (t, J = 6.4 Hz, 3H); 13C NMR (CD3OD) δ 173.2 (d), 
137.8 (m), 128.4 (m), 127.3 (m), 119.2 (m), 57.0 (d), 36.6 (d), 31.6 (d), 30.5 (s), 29.2 (s), 
29.0 (m), 25.5 (d), 24.5 (s), 24.0 (s), 23.3 (s), 13.3 (s); 31P NMR (CD3OD) δ 10.2 (d, J = 
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79.5 Hz, 1P); 19F NMR (CD3OD) δ 195.30 (dd, J = 78.2, 45.5 Hz, 1F); MS (ESI) m/z 
360.3 (M++1); HRMS for  C17H28FNO4P (M++1): found 360.1741, calcd 360.1740. 
 
3.5.21 Fluoro(4-tetradecanamidophenyl)methylphosphonic acid (3a) 
 
1H NMR (CD3OD) δ 7.40-7.54 (m, 4H), 5.45 (dd, J = 45.2, 8.4 Hz, 1H), 2.85-
2.95 (m, 1H), 2.34 (d, J = 7.6 Hz, 2H), 1.85-1.98 (m, 2H), 1.75-1.83 (m, 2H), 1.63-1.73 
(m, 4H), 1.12-1.25 (m, 24H), 0.87 (t, J = 6.4 Hz, 3H); 13C NMR (CD3OD/CDCl3) δ 173.3 
(s), 127.4 (s), 119.3 (d), 50.0 (s), 36.8 (s), 31.7 (s), 30.5 (s), 29.4 (s), 29.4 (s), 29.3 (s), 
29.2 (s), 29.0 (s), 25.6 (s), 24.5 (s), 24.0 (s), 13.3 (s); 31P NMR (CDCl3) δ 14.3 (d, J = 
77.9 Hz, 1P); 19F NMR (CDCl3) δ 191.30 (dd, J = 78.2, 45.5 Hz, 1F); MS (ESI) m/z 
416.3 (M++1); HRMS for  C21H36FNO4P (M++1): found 416.2357, calcd 416.2366. 
 





1H NMR (CDCl3) δ 9.31 (s, 1H), 7.50 (d, J = 8.4 Hz, 2H), 7.35 (d, J = 1.6 Hz, 
2H), 4.81 (d, J = 12.8 Hz, 1H), 4.13-4.22 (m, 2H), 3.87-3.97 (m, 1H), 3.71-3.82 (m, 1H), 
2.34 (d, J = 7.6 Hz, 2H), 1.56-1.68 (m, 2H), 1.12-1.25 (m, 23H), 1.08 (t, J = 7.8 Hz, 3H), 
0.80  (t, J = 7.2 Hz, 3H); 13C NMR (CDCl3) δ 172.6 (s), 139.8 (s), 130.0 (s), 128.4 (s), 
119.8 (s), 64.4 (s), 63.9 (s), 41.9 (s), 40.3 (s), 37.4 (s), 31.9 (s), 29.6 (s), 29.5 (s), 29.4 (s), 
29.3 (s), 25.6 (s), 22.6 (s), 16.4 (s); 31P NMR (CDCl3) δ 16.83 (s, 1P); MS (ESI) m/z 




methylphosphonic acid (1d) 
 
1H NMR (CD3OD) δ 7.50-7.60 (m, 2H), 7.38-7.43 (m, 2H), 4.34 (d, J = 15.2 Hz, 
1H), 2.98-3.05 (m, 1H), 2.36 (d, J = 8.0 Hz, 2H), 1.95-2.03 (m, 2H), 1.80-1.85 (m, 2H), 
1.56-1.68 (m, 4H), 1.12-1.25 (m, 24H), 0.89  (t, J = 7.2 Hz, 3H); 13C NMR (CD3OD) δ 
173.3 (s), 127.4 (d), 127.3 (s), 119.1 (s), 50.0 (s), 36.6 (s), 31.7 (s), 30.5 (s), 29.4 (s), 29.3 
(d), 29.2 (s), 29.1 (s), 28.9 (s), 25.5 (s), 24.5 (s), 23.9 (s), 22.3 (s), 13.0 (s); 31P NMR 
(CD3OD) δ 20.8 (s, 1P); MS (ESI) m/z 476.2 (M++1); HRMS for  C21H36BrNO4P (M++1): 
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PHOSPHOROTHIOATE ANALOGUES OF sn-2 RADYL 
LYSOPHOSPHATIDIC ACID (LPA) AS 
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Herein, I describe an efficient method for the synthesis of metabolically stabilized 
sn-2 radyl phosphorothioate analogues of lysophosphatidic acid (LPA). The 
pharmacological properties of these analogues were characterized by Dr. Aoki’s group at 
Tohoku University for subtype-specific LPAR agonist activity using AP-TGFα release 
assay in HEK293 cells. Compared to 1-oleoyl-2-O-methyl-glycerophosphothioate (sn-1 
OMPT) analogues previously prepared, sn-2 radyl OMPT analogues showed similar 
agonist activity for LPA3/P2Y5. Most importantly, sn-2 alkyl OMPT analogues are the 
very potent LPA5 agonists. The availability of new sn-2 radyl OPMT analogues expands 
the scope of structure-activity studies and will further refine the molecular nature of 
pligand-recetor interactions for this class of GPCRs. 
 
4.2 Introduction 
As we discussed in Chapter 1, all LPARs are important potential drug targets. 
Hence, both LPAR agonists and antagonists have the potential for the new drug 
development. Herein, in this chapter, we made a set of compounds which showed 
agonists activies at LPA3, LPA5 and P2Y5. LPA3 has been introduced in our previous 
studies.1,2 Hence, only LPA5 and P2Y5 will be mainly discussed in this chapter.  
GPR92/LPA5 is widely expressed in murine tissues such as embryonic brain, 
small intestine, skin, spleen, stomach, thymus, lung, heart, liver, and embryonic stem 
cells.3 Recent studies indicated that two other lipid-derived molecules, farnesyl 
pyrophosphate and narachidonylglycin, were characterized as LPA5 ligands.4 However, 
the following studies confirm that LPA5 is a bona fide LPAR which can also be activated 
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by farnesyl pyrophosphate at much higher concentrations compared to LPA 18:1.5,6 The 
biological function of the agonistic activity of alternative ligands is unclear yet. The 
studies reveal LPA5 may play an important role in the response of neuropathic pain and 
human platelet activation.3,7  
Human P2Y5 was originally reported as an orphan GPCR sharing the highest 
sequence homology with GPR23/P2Y9/LPA4, which strongly indicated that LPA would 
be a ligand for P2Y5.8 In a recent unbiased genetic search study, several mutations in the 
P2Y5 gene were found to correlate with autosomal recessive wooly hair. These studies 
clearly revealed the involvement of human P2Y5 in the regulation of hair follicle 
development and hair growth and implicated LPA signaling in this pathway.8 However, 
the molecular mechanism that LPA-mediated hair follicle formation is still elusive. 
Hence, the development of more stable, potent agonists/antagonists for emerging LPARs 
is eagerly awaited. The comparison of the activation properties of P2Y5 by sn-1 and sn-2 
LPA analogues suggested that sn-2-substited LPA analogues were more potent and more 
efficacious than their corresponding sn-1 LPA analogues. In addition, the 
phosphorothioate analogues of LPA, which were previously reported as LPA3-selective 
agonist, were more potent at the P2Y5 receptor than LPA (18:1)1,2 (Figure 4.1). Herein, 
we describe the synthesis and pharmacology of three phosphorothioate analogues of sn-2 
radyl lysophosphatidic acid (LPA) (Figure 4.2). Interestingly, except their agonist 
activities at P2Y5 and LPA3, the two alkyl sn-2 phosphorothioate analogues exhibited 


























































Figure 4.2. Phosphorothioate analogues of sn-2 radyl LPA. 
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4.3 Chemical Synthesis 
For initial evaluation for sn-2 radyl OMPT, the racemic targets were synthesized. 
The synthetic strategies for the preparation of the phosphorothioate targets were based on 
two critical considerations. First, by using the phosphoramidite methodology, which has 
been widely explored in nucleic acid chemistry, the alcohol was efficiently 
phosphorylated by using trivalent phosphorus reagent. The resulting phosphite triester 
could be oxidized with elemental sulfur in situ to yield the corresponding 
phosphorothioate. Moreover, the use of 2-cyanoethyl phosphate protecting group, which 
could be removed under mild basic conditions, is another key strategy for the sn-2 radyl 
OPMT synthesis. 
As illustrated in Scheme 4.1, we selected commercially available racemic solketal 
(dimethyl-1,3-dioxolane-4-methanol) as our starting material. The synthesis of the 
common intermediate 7 involved a three-step sequence. Methylation of 1,2-O-
isopropylidene glycerol was performed using methyl iodide in DMF at room temperature 
to give methyl ether 5. 10 mol % p-TsOH in CH3OH was employed to remove the 
acetonide to obtain the 1,2-diol 6 in 88% isolated yield. To minimize the possible 
 
Scheme 4.1. Synthesis of Common Intermediate 7. Reagents and conditions: (a) CH3I, 
NaH, DMF, 5 h at room temperature, 75%; (b) p-TsOH, CH3OH, overnight at room 
temperature, 88%; (c) TrCl, Et3N, dichloromethane, overnight at room temperature, 81%. 
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migration product from sn-2 to sn-1, a stable and easily removed protecting group should 
be selected for sn-1 hydroxyl. Herein, the primary hydroxyl group was selectively 
tritylated (TrCl, Et3N) producing compound 7. The typical aromatic triphenyl signal 
showed in 1H and 13C NMR, which suggested the correct compound we made. The trityl 
group could be cleaved by the treatment with TFA at room temperature for 1 h. 
With the compound 7 in hand, formation of the ether to obtain intermediate 8 was 
performed in the presence of sodium hydride (Scheme 4.2). Then the trityl group was 
removed under TFA conditions to provide alcohol 9. In this reaction, more polar spot 
showed on TLC, meanwhile, the aromatic signal disappeared from 1H and 13C NMR 
spectrum. Then alcohol 9 was phosphorylated with phosphoramidite. The resulting 
phosphoramidite triester was oxidized with elemental sulfur to obtain the corresponding 
phosphorothioate triester 10. In the final step, cyanoethyl ester groups were cleaved under 
aprotic basic conditions (tert-butyl amine in CH3CN) for 72 h to give the desired 
phosphorothioate analogue of LPA 1 and 2. 
In Scheme 4.3, acylation of sn-2 hydroxyl group with oleic acid was conducted in 
dichloromethane in the presence of DCC and DMAP to yield intermediate 11 in an 
excellent yield. The deprotection of trityl group under TFA condition in dichloromethane 
was performed with the minor migration product observed. The migration product was 
removed by the purification on silica gel and pure intermediate 12 was achieved. Then 
the final target ester analogue 3 was prepared from the precursor 12 in the analogous 













































Scheme 4.2. Synthesis of sn-2 alkyl Phosphorothioate Analogues 1 and 2. Reagents and 
conditions: (a) RI, NaH, DMF overnight at room temperature, 43-57%; (b) TFA, 
dichloromethane, 1 h at room temperature, 77-91%; (c) di-(2-cyanoethyl)-N,N-
diisopropylphosphodiamidite, 1H-tetrazole; S, CS2, pyridine, two steps, 82-86 %; (d) t-




Scheme 4.3. Synthesis of sn-2 acyl Phosphorothioate Analogues 3. Reagents and 
conditions: (a) Oleic acid, DCC, DMAP, dichloromethane, overnight at room temperature, 
94%; (b) TFA, dichloromethane, 1 h at room temperature, 81%; (c) di-(2-cyanoethyl)-
N,N-diisopropylphosphodiamidite, 1H-tetrazole; S, CS2, pyridine, two steps, 67 %; (d) t-
BuNH2, BTMSA, CH3CN, 72 h, 81 %.  
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All final targets synthesized were characterized by porton, carbon and phosphours 
NMR. 31P spectrum of phosphorothioate showed a singlet at around 60 ppm, which is 
consistent with that reported from previous references.1,2 
 
4.4 Receptor Activation Studies 
The sn-2 radyl OMPT were evaluated using TGFα-shedding assay to assess the 
activation and inhibition of LPA1, LPA2, LPA3, LPA4, LPA5, and P2Y5 expressed in 
HEK293 cells. AP-TGFα is initially produced as a transmembrane proform. Ligand 
stimulation induces phosphorylation of ADAM proteases and cleavage of AP-TGFα. 
Cleaved AP-TGFα can be quantified by measuring AP activity in the conditioned media 
using p-nitrophenyphosphate (p-NPP) as a substrate. Table 4.1 illustrates TPA-induced 
response elicited through the activation of human LPA1-5 and P2Y5 receptors. 
The two racemic OPMT analogues 2 and 3, both alkyl (18:1) and acyl (18:1), are 
potent LPA3 agonists. The potency is comparable to that of (2S) 1-acyl and (2S) 1-alkyl 
OMPT analogues and much higher than that of parent LPA (18:1). However, the sn-2 
alkyl (16:0) 1 showed almost 3-fold lower potency for LPA3. This trend is also exhibited 
for P2Y5, which is consistent with previous study9 and confirmed that both LPA3 and 
P2Y5 prefer unsaturated fatty acid. The most significant activity observed, however, was 
the discovery that both alkyl analogues 1 and 2 are LPA5 partial agonists, with the 
palmitoyl analogue 1 showing an EC50 value of 0.10 nM oleoyl analogue 2 showing an 
EC50 value of 0.11 nM for LPA5. To the best of our knowledge, these two new 
compounds are most potent LPA5 agonists and could be a useful pharmacological tool for 
the further study of this receptor. The potent agonist activities of both sn-1 and sn-2  
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Table 4.1. Pharmacological evaluation of the phosphorothioate analogues on LPA 
GPCRs in the TGFα-shedding assay. 
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OMPT analogues for LPA5 could provide additional evidence that LPA5 is a true LPAR.3-
5,10 
From previous work and this study,1,2 the two enantiomers of OMPT analogues 
displayed different agonistic activity significantly. Hence, it would be very important to 
identify which enantiomer of sn-2 radyl OMPT is responsible for the agonistic activity. 
The synthesis of pure enantiomer would be helpful for understanding the mechanism of 
this agonistic activity. 
 
4.5 Experimental Procedures 
All chemicals and solvents were purchased from Aldrich, Alfa Aesar or Acros 
Chemical Corporation and used without prior purification. Thin-layer chromatography 
was performed on precoated silica gel aluminum sheets (EM SCIENCE silica gel 60F254). 
Purification of compounds was carried out by normal phase chromatography (ISCO 
[Combiflash], Silica gel 230~400 mesh). NMR spectra were recorded using a Varian 
Mercury 400 at 400 MHz (1H), 101 MHz (13C), 162 MHz (31P), 376 MHz (19F) at 25oC. 
Chemical shifts are given in ppm with TMS as internal standard (δ=0.00); 31P, 85% 
H3PO4 (δ=0.00). NMR peaks were assigned by MestRe-C (4.9.9.9). Low and high-
resolution mass spectra were obtained on HP5971A MSD and Finnigan MAT95 double 
focusing mass spectrometer instruments, respectively. 
 
4.5.1 2-(Hexadecyloxy)-3-methoxypropan-1-ol (9a) 
To a solution of 3.7 g (10.6 mmol, 1 equiv.) of 1-methoxy-3-(trityloxy)propan-2-
ol (7) in 40 mL of DMF was added sodium hydride (60 % in mineral oil, 664 mg, 16.1 
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mmol, 1.15 equiv.). Then the reaction mixture was stirred at room temperature for 1 h 
before 4.31 g (12.2 mmol, 1.2 equiv.) 1-iodohexadecane in 10 mL DMF was added. The 
mixture was stirred for additional 4 h before 1N HCl (100 mL) was added to quench the 
reaction, and the mixture was extracted with 100 mL of EtOAc twice. The combined 
organic extracts were washed with saturated NaHCO3 solution, followed by a saturated 
NaCl solution. Solvent was removed at reduced pressure and the crude mixture was 
purified on silica column (EtOAc-Hex, 0 to 5%) to give crude 8a (3.46 g, 6.04 mmol, 
57%), which was directly dissolved into 50 mL dichloromethane and then 50 mL TFA. 
The reaction mixture was stirred at room temperature for 1 h. Then solid sodium 
bicarbonate was added slowly to neutralize the reaction mixture, followed by 100 mL 
water. The organic layer was separated and the water layer was washed by 
dichloromethane (100 mL) twice. All organic layers were combined and dried over 
sodium sulfate. The mixture was concentrated and the residue was loaded on silica 
column (EtOAc-Hex, 0 to 30%) to crude 9a (1.92 g, 5.82 mmol, 91%). 
 
1H NMR (CDCl3) δ 3.70-3.75 (m, 1H), 3.55-3.65 (m, 2H), 3.42-3.52 (m, 4H), 
3.34 (s, 3H), 2.23 (s, 1H), 1.51-1.58 (m, 2H), 1.20-1.38 (m, 26H), 0.86 (t, J = 6.4 Hz, 3H); 
13C NMR (CDCl3) δ 78.3 (s), 72.6 (s), 70.4 (s), 62.7 (s), 59.3 (s), 31.9 (s), 29.5 (m), 26.0 












Compound 9b was synthesized in the analogous fashion described previously for 
compound 9a. 
1H NMR (CDCl3) δ 5.29-5.37 (m, 2H), 3.70-3.75 (m, 1H), 3.55-3.65 (m, 2H), 
3.42-3.52 (m, 4H), 3.35 (s, 3H), 1.90-2.08 (m, 4H), 1.51-1.62 (m, 2H), 1.20-1.38 (m, 
22H), 0.87 (t, J = 6.8 Hz, 3H); 13C NMR (CDCl3) δ 129.8 (d), 78.2 (s), 72.7 (s), 70.4 (s), 
62.8 (s), 59.4 (s), 31.9 (s), 29.5 (m), 27.1 (d), 26.1 (s), 22.7 (s), 14.1 (s); MS (ESI) m/z 
379.4 (M+Na+). 
 













Di(2-cyanoethyl) diisopropylphosphorodiamidite (100 mg, 0.3 mmol, 0.3 eqiuv.) 
was added under an argon atmosphere to a solution of 9a (356 mg, 1 mmol) and 1H-
tetrazole (70 mg, 1 mmol) in 10 mL dry dichloromethane. After stirring for 1 h, sulfur 
(32 mg, 1 mmol) and CS2/pyridine (0.2 mL, 1:1 v/v) were added. After stirring at room 
temperature for 2 h, the reaction mixture was filtered and the filtrate was washed with 
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brine, dried over sodium sulfate, and concentrated. The residue was purified on silica 
column (EtOAc/Hex/dichloromethane 1:2:2 v/v/v) gave 10a as a colorless oil 130 mg 
(0.246 mmol, 82%).  
1H NMR (CDCl3) δ 4.21-4.35 (m, 5H), 4.08-4.12 (m, 1H), 3.51-3.62 (m, 3H), 
3.46-3.48 (m, 2H), 3.37 (s, 3H), 2.78 (t, J = 6.0 Hz, 4H), 1.51-1.71 (m, 2H), 1.20-1.38 (m, 
26H), 0.88 (t, J = 6.8 Hz, 3H); 13C NMR (CDCl3) δ 116.3 (d), 71.3 (s), 70.7 (s), 68.0 (d), 
62.5 (m), 59.4 (s), 31.9 (s), 29.5 (m), 26.0 (s), 22.7 (s), 19.5 (s), 19.4 (s), 14.1 (s); 31P 
NMR (CDCl3) δ 67.7 (1P); MS (ESI) m/z 533.4 (M++1). 
 
4.5.4 O,O-Bis(2-cyanoethyl) O-3-methoxy-2-((Z)-octadec- 













Coumpound 9b was synthesized in the analogous fashion described previously for 
compound 10a. 
1H NMR (CDCl3) δ 5.29-5.37 (m, 2H), 4.21-4.35 (m, 4H), 3.70-3.75 (m, 1H), 
3.55-3.65 (m, 2H), 3.42-3.52 (m, 2H), 3.35 (s, 3H), 2.78 (t, J = 6.0 Hz, 4H), 1.90-2.08 (m, 
4H), 1.51-1.62 (m, 2H), 1.20-1.38 (m, 24H), 0.87 (t, J = 6.8 Hz, 3H); 13C NMR (CDCl3) 
δ 130.0 (d), 116.3 (d), 71.3 (s), 70.7 (s), 68.0 (d), 62.5 (m), 59.4 (s), 34.2 (s), 31.9 (s), 
29.5 (m), 26.0 (s), 22.7 (s), 19.5 (s), 19.4 (s), 14.1 (s); 31P NMR (CDCl3) δ 67.7 (1P); MS 
(ESI) m/z 559.2 (M++1). 
  
91
4.5.5 Sodium O-2-(hexadecyloxy)-3-methoxypropyl  
O-hydrogenphosphorothioate (1) 
 
tert-Butylamine (0.2 mL) was added to a solution of compound 10a (100 mg, 0.17 
mmol) in CH3CN (1 mL) under N2 followed by the addition of bistrimethylsilylacetamide 
(0.2 mL). After 48 h, the reaction mixture was concentrated and the residue was purified 
by chromatography (EtOAc/CH3OH, 8:1 to 1:1 v/v) to afford 63 mg of 1 as a light yellow 
oil (0.14 mmol, 84%). 
1H NMR (CDCl3) δ 4.05-4.22 (m, 2H), 3.41-3.75 (m, 5H), 3.37 (s, 3H), 1.51-1.71 
(m, 2H), 1.20-1.38 (m, 26H), 0.88 (t, J = 7.2 Hz, 3H); 13C NMR (CDCl3) δ 72.4 (s), 70.4 
(s), 59.5 (s), 31.9 (s), 29.5 (m), 25.9 (s), 22.7 (s), 14.1 (s); 31P NMR (CDCl3) δ 52.6 (1P); 
MS (ESI) m/z 449.4 (M++1). 
 
4.5.6 Sodium O-3-methoxy-2-((Z)-octadec-9-enyloxy)propyl  
O-hydrogenphosphorothio- ate (2) 





1H NMR (CDCl3) δ 5.29-5.37 (m, 2H), 4.15 (m, 2H), 3.48-3.78 (m, 5H), 3.42 (s, 
3H), 1.90-2.08 (m, 4H), 1.51-1.62 (m, 2H), 1.20-1.38 (m, 22H), 0.87 (t, J = 6.8 Hz, 3H); 
13C NMR (CDCl3) δ 129.8 (d), 71.8 (s), 71.0 (s), 59.5 (s), 32.6 (s), 31.9 (s), 29.5 (m), 
27.2 (d), 25.9 (s), 22.7 (s), 14.1 (s); 31P NMR (CDCl3) δ 62.6 (1P); MS (ESI) m/z 475.4 
(M++1). 
 












To a solution of 1-methoxy-3-(trityloxy)propan-2-ol 7 (1.13 g, 3.27 mmol, 1 
equiv.) and oleic acid (1.23 mL, 3.92 mmol, 1.2 equiv.) in dry dichloromethane (10 mL) 
was added a solution of DCC (890 mg, 4.25 mmol, 1.3 equiv.) and DMAP (40 mg, 0.33 
mmol, 0.1 equiv.) in dry dichloromethane (4 mL). The solution was stirred for 16 h at 
room temperature, filtered, and concentrated in vacuo, and the residue was purified on 




1H NMR (CDCl3) δ 7.40-7.45 (m, 6H), 7.20-7.35 (m, 9H), 5.32-5.40 (m, 2H), 
5.20-5.23 (m, 1H), 3.51-3.61 (m, 2H), 3.31 (s, 3H), 3.25 (d, J = 16.8 Hz, 2H), 2.36 (dt, J 
= 2.0, 7.6 Hz, 2H), 2.02-2.12 (m, 4H), 1.51-1.71 (m, 2H), 1.20-1.38 (m, 20H), 0.88 (t, J = 
6.8 Hz, 3H); 13C NMR (CDCl3) δ 173.9 (d), 143.8 (s), 129.8 (d), 128.6 (s), 127.8 (s), 
127.0 (s), 86.5 (s), 71.6 (d), 62.6 (s), 59.1 (s), 34.5 (s), 31.9 (s), 29.5 (m), 27.2 (d), 25.0 
(s), 22.7 (s), 14.1 (s); MS (ESI) m/z 635.6 (M+Na+). 
 
4.5.8 1-Hydroxy-3-methoxypropan-2-yl (Z)-nonadec-10-enoate (12) 










1H NMR (CDCl3) δ 5.33-5.42 (m, 2H), 4.98-5.03 (m, 1H), 3.79-3.84 (m, 2H), 
3.58-3.68 (m, 2H), 3.37 (s, 3H), 2.78 (t, J = 6.0 Hz, 4H), 2.40 (t, J = 7.6 Hz, 3H), 2.02-
2.12 (m, 4H), 1.51-1.71 (m, 2H), 1.20-1.38 (m, 26H), 0.88 (t, J = 6.8 Hz, 3H); 13C NMR 
(CDCl3) δ 173.9 (d), 130.0 (d), 73.4 (s), 71.7 (s), 68.7 (d), 65.3 (s), 62.4 (d), 59.3 (d), 







4.5.9 O,O-Bis(2-cyanoethyl) O-3-methoxy-2-((Z)-oleoyloxy)propyl  
phosphorothioate (13) 
















1H NMR (CDCl3) δ 4.21-4.35 (m, 5H), 4.08-4.12 (m, 1H), 3.51-3.62 (m, 3H), 
3.46-3.48 (m, 2H), 3.37 (s, 3H), 2.78 (t, J = 6.0 Hz, 4H), 1.51-1.71 (m, 2H), 1.20-1.38 (m, 
26H), 0.88 (t, J = 6.8 Hz, 3H); 13C NMR (CDCl3) δ 173.1 (s), 130.0 (d), 116.4 (s), 70.1 
(m), 67.0 (d), 62.6 (d), 59.4 (s), 34.2 (s), 31.9 (s), 29.5 (m), 27.2 (d), 24.8 (d), 22.7 (s), 
19.5 (s), 19.4 (m), 14.1 (s); 31P NMR (CDCl3) δ 68.0 (1P); MS (ESI) m/z 573.4 (M++1). 
 
4.5.10 Sodium O-3-methoxy-2-((Z)-oleoyloxy)propyl  
O-hydrogenphosphorothioate (3) 
















1H NMR (CDCl3) δ 5.21-5.40 (m, 2H), 4.01-4.21 (m, 2H), 3.48-3.61 (m, 2H), 
3.40-3.50 (m, 1H), 3.37 (s, 3H), 2.15-2.21 (m, 2H), 1.90-2.08 (m, 4H), 1.51-1.62 (m, 2H), 
1.20-1.38 (m, 20H), 0.88 (t, J = 6.8 Hz, 3H); 13C NMR (CDCl3) δ 130.0 (s), 129.7 (s), 
59.4 (s), 34.6 (s), 31.9 (s), 29.5 (m), 27.2 (d), 24.9 (s), 22.7 (s), 14.1 (s); 31P NMR (CDCl3) 
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DEVELOPMENT OF ACTIVITY-BASED PROBES 
















Nucleotide pyrophosphatases/phosphodiesterases (NPP) represent a group of 
widely distributed proteins that catalyze pyrophosphate and phosphate diester hydrolysis, 
which are either expressed as transmembrane-ectoenzyme or as secreted protein. NPP2 
(ATX) is the only member in this family that has extracellular lysophospholipase D 
activity, which converts lysophosphatidylcholine (LPC) into lysophosphatidic acid (LPA). 
Activity-based probes (ABP) are active site-directed probes to profile the functional state 
of enzymes in complex proteomes. In this chapter, fluorophosphonate and vinyl sulfone 
analogues of LPC were designed to serve as ABP to identify ATX from other NPP 
members. The study revealed that fluorophosphonate displayed low shelf-life, which was 
hydrolyzed rapidly. Vinyl sulfone analogues of LPC showed irreversible kinetic. 
However, the further evidences are needed to support irreversible inhibition. In addition, 
Dr. Mandi Murph’s lab further examined the use of these analogues to reduce migration 
of OVCAR-3 human ovarian carcinoma and MDA-MB-231 breast cancer cell lines in 
vitro. Vinyl sulfone analogues inhibited cell migration in both cell lines effectively. The 
further studies for vinyl sulfone analogues are ongoing. 
 
5.2 Introduction 
 Nucleotide pyrophosphates/phosphodiesterases (NPP) consist of a group of 
widely and phylogenetically conserved proteins, which hydrolyze pyrophosphate bonds 
(such as ATP) and phosphodiester bonds. A recent study indicates that NPP2 (ATX) has 
extracellular lysophospholipase D activity which converts lysophosphatidylcholine (LPC) 
into lysophosphatidic acid (LPA).1 To date, seven members have been identified in 
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mammals which numbered in chronological order. All NPP family members contain a 
large catalytic domain. NPP1-3 share a very similar primary structure, including a large 
extracellular C-terminal domain (800 residues), a single transmembrane domain 
(approximately 20 residues), and a short intracellular N terminal region (10-80 residues).2 
NPP1-3 consists of two somatomedin-B-like domains in their N terminus, which 
probably involved in potential protein interactions,3 a catalytic domain with the 
conserved catalytic threonine4 and a nuclease-like domain (Figure 5.1). The single 
catalytic site (Thr210 for ATX) mediating both nucleotide pyrophosphatase and 
phosphodiesterase activities4 is critical for ATX’s lysoPLD activity as well.5 Although 
NPP1 and NPP3 have a transmembrane domain in their N terminus, they are also 
membrane-bound ectoenzymes due to their type-II orientation.3 NPP2 is not a 
transmembrane protein but is synthesized as a pre-pro-enzyme. NPP2 activity is activated 
by the cleavage of the N-terminal signal peptide and further trimming by a furine-type 
protease.6 Similar to NPP2, the N-terminal hydrophobic sequences of NPP4-7 is a signal 
peptide. NPP4-7 are shorter proteins which contain a type I transmembrane domain in 
their C terminus and their catalytic domain faces the extracellular space.3 NPP4 and 
NPP5, which was discovered after NPP1-3 and showed significantly different structures 
in their N terminus, have been described as putative NPP ectoenzymes based on their 
sequence homology with the previously identified members of the family.4 The efforts 








Figure 5.1. Domain structure and function of ENPPs (Stefan, C.; Jansen, S.; Bollen, M. 
NPP-type ectophosphodiesterases: unity in diversity. Trends in Biochem. Sci. 2005, 30, 
542-550. Reprinted with permission) 
 
Despite their fundamental importance, the reaction mechanism of phosphoesters 
or ATP hydrolysis is not fully understood yet. Similar to alkaline phosphatase (AP), a 
two stepwise mechanism has been proposed for NPP hydrolysis.4 (Figure 5.2) First, 
nucleophilic attack by the metal-activated hydroxyl group of the catalytic-site threonine 


















































































Figure 5.2. Hydrolysis mechanism by mouse NPP1 from a homology model. (Adapted 
from Gijsbers, R.; Ceulemans, H.; Stalmans, W.; Bollen, M. Structural and catalytic 
similarities between nucleotide pyrophosphatases/phosphodiesterases and alkaline 
phosphatases. J. Biol. Chem. 2001, 276, 1361-1368.) 
 
formation of a (di)ester linkage with the phosphate group. In the second catalytic step, a 
water molecule coordinated by the second metal attacks the phosphate, resulting in 
hydrolysis of the intermediate. Meanwhile, the catalytic site threonine/serine is 
regenerated and a phosphorylated product is released. Although ATX shows 
phosphodiesterase, pyrophosphatase and ATPase activities, nucleotide and other model 
compounds are relativity poor substrates for ATX. 
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The substrates of NPPs include ATP, LPC, sphingomyelin and 
glycerophosphorylcholine among others.3 Interestingly, two distinct hydrolysis ways of 
ATP by NPP1 have been identified. The products of hydrolysis are either AMP+PPi or 
ADP+Pi, respectively, depending on how ATP approaches the catalytic site. LPC is 
another example which can be hydrolyzed in two ways. As we discussed before, LPC 
could be hydrolyzed into LPA and choline by ATX with its extracellular 
lysophospholipase-D activity.5 Meanwhile, LPC also could be hydrolyzed into a 
monoacylglycerol (MAG) and choline phosphate by NPP6 and NPP7. Surprisingly, for 
these important class of enzymes, the studies for NPP substrate specify are very 
limited.5,7 As we discussed previously that the hydrolysis of lysophospholipids, 
nucleotides, and phosphodiesters depends on the same catalytic-site residues (serine for 
NPP 6 and threonine for other NPPs) which are conserved among NPPs.5 Domain-
swapping experiments indicated that the residues close to the catalytic domains of NPP1 
and NPP2 play a key role in substrate-specification.7  
Although genomics advances have presented the promise of improving efficiency 
for drug target identification, understanding the function and structure of enormous 
proteins produced from a complete genome represents one of the principal challenges for 
the field of proteomics. Activity-based protein profiling (ABPP) is a chemical strategy 
for proteomics that utilizes active site-directed probes to profile the functional state of 
enzymes in complex proteomes.8,9 To date, activity-based proteomic probes have been 
developed for several important enzyme classes.10 In their most basic form, chemical 
probes consist of three general elements: a reactive group that covalently labels the active 
sites of the enzymes; a flexible linker that can modulate reactivity and specificity of the 
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reactive group; and a reporter group for identification and purification of probe-labeled 
enzymes.11 In probe design, an alkyne-tag instead of most common used biotin, 
fluorescent, and radioactive tags was employed to avoid the limitation to applying 
traditional ABPs because of their bulky reporter tags which limit probe uptake and 
distribution in cells and tissues. In this strategy, the linker was generated from copper(I)-
catalyzed azide alkyne [3+2] cycloaddition reaction (“click chemistry”) 12 after the ABPs 
have undergone reaction with the protein of interest.  
As we mentioned previously, ATX is the only NPP member which shows 
lysophospholipase D activity.1 However, LPC, the substrate of ATX, is hydrolyzed into a 
MAG and choline phosphate by NPP6 and NPP7 (lysophospholipase-C activity) as well3 
(Figure 1.4). Hence, the objective for this study is to discover an ABP which could 
identify NPP2 from other NPP members. Although LPC could be identified by NPP2, 
NPP6, and NPP7, the cleavage site of NPP2 is different from that of NPP6 and NPP7 
(Figure 5.3). Fluorophosphonates have been widely used for irreversible active site-
directed enzyme inhibitor that inhibits nearly all serine hydrolases and serine proteases.13 
The site A of fluorophosphonate (cleavage site of LPC by NPP6 and NPP7) is methylene 
group, which is resistant to hydrolysis. Accordingly, we hypothesized that a 
fluorophosphonate with choline head might serve as a potent and selective probe for 
identifying NPP2 from NPP6 and NPP7. Synthesis for fluorophosphonate is challenging 
due to the high reactivity of P-F bond. We demonstrated that fluorophosphonate with 
choline head is hydrolyzed to their according phosphonic acid rapidly, which failed to be 
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Figure 5.3. fluorophosphonate and vinyl sulfone analogues of LPC. 
 
 
probably due to the high hydroscopic choline salt, which accelerates the hydrolysis 
process. 
Vinyl sulfone (VS) derivatives have been widely characterized as irreversible 
inhibitors of cysteine protease.14 The mechanism of this irreversible inhibition depends 
on the vinyl sulfone acting as a Michael acceptor covalently reacting with the soft 
nucleophiles such as thiols.15,16 Further studies indicate that peptide vinyl sulfone 
inhibitors also modify the active site threonine of the Escherichia coli HsIV homologue 
and Rhodococcus proteasome.17,18 Similar to the inhibition of cysteine protease, the 
inhibition of proteasome by peptide vinyl sulfone also involves covalent modification of 
the N-terminal threonine of the catalytic β subunits, via a Michael addition.14,17 In a 
recent study, crystal structure of HslUV complexed with a vinyl sulfone inhibitor was 




Figure 5.4. Mechanism of inhibition of proteasome by vinyl sulfones. (Powers, J. C.; 
Asgian, J. L.; Ekici, Ö. E.; James, K. E. Irreversible Inhibitors of Serine, Cysteine, and 
Threonine Proteases. Chem. Rev., 2002, 102, 4639-4750. Reprinted with permission) 
 
 
reacted with the vinyl sulfone inhibitor 4-iodo-3-nitrophenyl acetyl-leucinyl-leucinyl- 
leucinyl-vinylsulfone (NLLLVS).19 All these evidences indicated that vinyl sulfone might 
be a potential warhead (reactive group) for ABP, which identified NPP family with 
conserved catalytic threonine. Herein, we switched our focus to make a set of vinyl 
sulfone which closely isosteric to the substrate lysophosphatidylcholine of ATX. 
In order to incorporate specific features into the design, we embarked on the 
following strategies. We have demonstrated that the choline of LPC is crucial for the 
substrate identification. Hence, the choline head of LPC should be retained in newly 
designed analogues, which is important for the potency. Unlike the vinyl sulfones used as 
ABP in cysteine protease, which have substitutions on both sides of vinyl group, a 
terminal vinyl structure was designed in our ABP for NPP family (Figure 5.3). First, the 
  
106
terminal vinyl group shows the maximum exposure to the enzyme with the least 
hinderance. Secondly, the unsubstituted end of double bond exhibits the most reactivity 
toward threonine. The motivation of the substitution of the phosphate headgroup by 
sulfone includes two aspects. First of all, the sulfone analogues are resistant to the 
hydrolysis enzyme compared to phosphate. Meanwhile, the strong electron-withdrawing 
group sulfone could activate the double bond which reacts with nucleophiles. Herein, we 
propose that the choline head could be identified by ATX when vinyl sulfones approach 
the active site. In addition, similar to the interaction between phosphonate and metal of 
the ATX, the sulfone head could form the same interaction which stabilizes the substrate 
further. Thus, metal-activated hydroxyl group of the catalytic-site threonine could attack 
the vinyl sulfone and the covalent bond will be formed accordingly.  
 
5.3 Chemical Synthesis 
5.3.1 Chemical Synthesis of Fluorophosphonate 
We envisioned a strategy by installing the methyl group before the phosphonate 
formation and employing D-mannitol, an inexpensive chiral building block, as the 
starting material. Our first objective was the preparation of aldehyde 5 staring from D-
mannitol. Adapting a known protocol,20 selective protection of D-mannitol to afford 
1,3:4,6-di-O-benzylidene-D-mannitol 2 was achieved by using catalytic sulfuric acid in 
the moderate yield (Scheme 5.1). The methylation of hydroxyl groups proceeds smoothly 


































Scheme 5.1. Synthesis of aldehyde 5. Reagents and conditions: (a) benzaldehyde, cat 
H2SO4, DMF, 51%; (b) CH3I, NaH, DMF, 96%; (c) Et3SiH, BF3.Et2O, dichloromethane, 
55%; (d) NaIO4, THF/CH3OH/H2O, 81%. 
 
iodide condition. The regioselective reductive cleavage of benzylidene acetals to form 
monoprotected diol can be achieved by using various reagents systems.21 Here, treatment 
of intermediate 3 with BF3•Et2O in combination of Et3SiH at 0 oC was employed to 
selectively open the acetal ring to provide diol 4 in 55% yield.22 Then the aldehyde 5 
could be achieved by oxidative cleavage of 4 subsequently. 
Aldehyde 5 was transformed to the vinyl bromide 7 after two steps (Scheme 5.2). 
First, treating the aldehyde 5 with triphenylphosphine and carbon tetrabromide via the 
known procedure afforded dibromoalkene 6 in 93% yield.23 Then intermediate 6 was 
converted to an inseparable mixture of E and Z monobromo alkene 7 using 4 equiv. of 
dimethyl phosphite in the presence of triethylamine.24 Vinylphosphonates as synthetic 
intermediates for biologically active compounds synthesis has been widely studied over 
the past two decades.25 Palladium-catalyzed phosphorus-carbon bond formation between 





































Scheme 5.2. Synthesis of phosphonate 9. Reagents and conditions: (a) CBr4, PPh3, 
dichloromethane, 93%; (b) dimethyl phosphite, Et3N, DMF, 59%; (c) Pd(dppf)2, 
propylene oxide, diethylphosphite, 70 oC for 6 h, 80%; (d) Pd/C, CH3OH, H2, 100%. 
 
 
mixture 7 and diethyl phosphonate to the commercial Pd(dppf)2, propylene oxide in 
tetrahedronfuran at 70 oC for 6 h gave the vinylphosphonates 8 as a E/Z mixture (ratio 9:1) 
in 80% yield. (E)-bromide is more reactive than its (Z)-isomer: thus a mixture of (E)- and 
(Z)-bromide 7 leads to the major (E)-isomer of the vinylphosphonate 8. The deprotection 
of benzyl group and reduction of double bond was performed simultaneously under the 
hydrogenation condition (Pd-C, H2, 1atm) to afford 9 in quantitative yield. With the 
common intermediate 9 in hand, the acyl chain could be attached conveniently. 
Compound 9 was acylated with oleic acid in the presence of the DCC and DMAP 
to provide phosphonate 10 (Scheme 5.3). The conversion of 10 to 13 involved a three-
step sequence and no intermediates need be isolated. First, treatment of each phosphonate 
10 with TMSBr in dichloromethane and subsequent addition of 5% aq methanol provided 
the phosphonic acid 11. Several approaches were available in the literature for the 












































Scheme 5.3. Synthesis of fluorophosphonate 13. Reagents and conditions: (a) Oliec acid, 
DCC, DMAP, dichloromethane, 99%; (b) TMSBr, dichloromethane; (c) CH3OH/H2O; (d) 
methyl-DAST, dichloromethane; (e) choline, Et3N, CH3CN, 55% for four steps from 10. 
 
difluorophosphonate 12 in the presence of Methyl-DAST at 0 oC for 10 min followed by 
rt 10 min, then the crude reaction was treated with 0.5 N HCl at 0 oC and organic layer 
was quickly dried to afford 12.28 The clean conversion was confirmed by both 19F and 31P 
NMR. This intermediate 12 was added immediately to the mixture of 1 equiv. choline 
and 1 equiv. Et3N in CH3CN to provide fluorophosphonocholine, which was used for 
next step without further purification. The 31P NMR spectrum of 13 has a doublet (22.45 
and 28.51 ppm) with coupling constants of 981 Hz, which are almost identical to the 
pattern in the 19F NMR, suggesting the existence of a P-F bond. However, these signals 
disappeared rapidly when the sample was exposed into the air. The corresponding 
phosphonic acid was observed. We proposed that the highly hydroscopic salt is the 




5.3.2 Chemical Synthesis of Vinyl Sulfone 
Recent studies showed that palladium or copper-promoted reaction of sulfinic 
acids with alkyl halides or triflates provides vinyl sulfone in good yield.29,30 However, 
harsh conditions (80 oC) were conducted in the synthesis. Our strategy for the synthesis 
of desired targets involves conversion of the key intermediate β-hydroxy sulfones 8 to 
vinyl sulfones 9. In addition, the choline salts 10 and 17 were prepared in the final step to 
avoid purification issue.  
Two different synthetic routes were carried out based on the availability of the 
starting materials. The vinyl sulfone analogues with C16:0, C18:1 and 11-yne 
hydrophobic chain were prepared as shown in Scheme 5.4. The formation of thioether 3 
could be performed by displacement of methyl-2 mercaptoacetate 1 with bromide in good 
yield (98%). Then the primary hydroxyl group was tritylated (TrCl, Et3N) to give 
compound 4. Conversion of sulfide 4 to sulfone 5 was accomplished by oxidation with 
mCPBA in dichloromethane. In order to alkylate compound 5 regioselectively, we chose 
sodium hydride as the base and the reaction could be performed at room temperature in 
moderate yield and the regioisomer was not detected.  
Next, the reduction of ester and removal of trityl group was carried out to give the 
diol 8. However, preliminary attempts to reduce ester were unsuccessful. Over reduction 
of hydroxyl to methyl was observed in both excess lithium aluminum hydride and sodium 
boron hydride. All excess reduction reagents, long reaction time and reaction temperature 
are possible the reason for over reduction. Hence, we screened a set of conditions, in 
which the variables are quantity of reduction reagents, the reaction time and reaction 
temperature. After a brief period of optimization, the moderate yields of reduction (34- 
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10c R=11-yne  
Scheme 5.4. Synthesis of Vinyl Sulfone Analogues 10. Reagents and conditions: (a) 
K2CO3, acetone, reflux, 2 h, 98%; (b)TrCl, triethylamine, dichloromethane, 94%;(c) 
mCPBA, dichloromethane, 0 oC to room temperature, 8 h, 95%; (d) NaH, RI, DMF, 72-
88%; (e) LiAlH4, diethyl ether, at 0 oC, 10 min, 34-51%; (f) TFA, dichloromethane, 2 h, 
66-81%; (g) MsCl, DIPEA, dichloromethane; (h) NaI, acetone; (i) DIPEA, EtOAc, 45-
81% for three steps; (j) trimethylamine in EtOH, dichloromethane, 4 days, 71-85%. 
 
 
51%) could be obtained by using 1 equiv. of lithium aluminum hydide in 
tetrahedronfuran at 0 oC for 10 min. The conversion of diols 8 to vinyl sulfone 9 involved 
a three-step sequence, although no intermediates need be isolated. Conversion of 8 to the 
corresponding mesylate and subsequent iodination afforded the iodo intermediates. Then 
the β-iodo sulfones were selectively eliminated by treating with diisopropylethylamine 
(DIPEA) in EtOAc to give the desired vinyl sulfones. On the contrary, γ-iodo sulfones 
  
112
were stable in the presence of DIPEA, which allowed us install choline head in the 
following step. In the end, the corresponding choline salts could be obtained by treating 
the remaining iodo group with trimethylamine in a mixture of ethanol and 
dichloromethane for 4 days. Recrystallization of crude salts from CH3OH-Et2O provided 
the final targets 10 as white solids. 
This robust route worked for alkyne 10c synthesis very well without any further 
modification. The 1H NMR spectrum of 10 showed two single peaks between 5.5 ppm to 
6.5 ppm. This pattern clearly indicated the existence of vinyl sulfone in the molecule. 
However, the proton peak for alkyne hydrogen in 10c was overlapped with other signals, 
which showed a multiplet pattern (3 protons between 2.13 ppm and 2.20 ppm). The 13C 
NMR spectrum of 10c showed the signal at 68.0 ppm, which matched the signal for the 
terminal alkyne with long hydrophobic chain (68.6 ppm for 1-hexyne). Moreover, we 
could get the evidence that we made the correct compound from the mass spectrum of 
10c (342.3, M+). 
In an effort to synthesize the shorter chain vinyl sulfone, we took the advantage of 
commercially available α-bromo carbonyl ester 12, which reacted with thiol directly to 
give corresponding sulfide (Scheme 5.5). Excess lithium aluminum hydride was 
employed to reduce ester groups to diols 14. Then final targets 17a and 17b were 
prepared from diol 14 in an analogous fashion described previously for the close 




Scheme 5.5. Synthesis of Vinyl Sulfone Analogues 17. Reagents and conditions: (a) 
K2CO3, acetone, reflux, 2 h, 89-93%; (b) LiAlH4, THF, at 60 oC, overnight, 88-90%; (c) 
mCPBA, dichloromethane, 0 oC to room temperature, 8 h, 77-81%; (d) MsCl, DIPEA, 
dichloromethane; (e) NaI, acetone; (f) DIPEA, EtOAc, 69-82% for three steps; (g) 
trimethylamine in EtOH, dichloromethane, 4 days, 58-72%. 
 
 
5.4 Biological Results 
The inhibition kinetic performed by Dr. Madan showed that the enzyme activity 
decreased in a time-dependent manner. However, the time course of inhibition is very 
rapid. Pre-incubating ATX with compound 10b for just 2 min results in complete 
inhibition. In addition, Dr. Madan reacted alkyne analogue compound 10c with azide in a 
standard click chemisty kit and run the reaction mixture on the SDS gel. While, the 
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inhibitor-ATX adduct was not observed on the gel. Interestingly, the mass of ATX-
inhibitor adduct was not detected either. Regard to the further experiments, the direct 
built-in fluorescent group attached on the target vinyl sulfone as the tag should be 
synthesized for detecting the inhibitor-ATX adduct on the SDS gel due to the reliability 
of click chemistry.  
The different hydrophobic chain length was synthesized to study the SAR. The 
inhibition of ATX by the vinyl sulfone lysophosphatidic choline analogues 10a, 10b, 10c, 
17a, and 17b was tested by using an ATX Inhibitor Screening Kit in a dose-response 
mode (Table 5.1). ATX activity was measured by the hydrolysis of the fluorogenic 
lysoPC analogue FS-3, which has a KM value of 6.3 μM.31 The results showed that all 
analogues except shorter-chain analogue 17b inhibited ATX effectively. Interestingly, 
C12:0 vinyl sulfone analogue 17a showed the best inhibition. (Ki = 1.79 μM ) Compared 
to the ATX inhibition by LPC analogues, C18:1 LPC showed the best inhibition.32 
Further studies around 10b were conducted in an effort to explore potency in 
functional assay and cell migration (Table 5.2). Compound 10b displayed inhibition 
activity for all the cell lines we tested. The IC50 is 0.39 μM for MDA-MB-231 breast 
cancer cell line. In addition, cell migration was measured using Ovcar-3 and MDA-MB-
231 for analogue 10b in wound scratch assay (Figure 5.5 and Figure 5.6). The analogue 
10b displays a signification reduction of cell migration (over 75%) at 5 μM in both 






Table 5.1. Inhibition of ATX phosphodiesterase activity by vinyl sulfone analogues.a 
 
 R Ki (μM) 
C18H35 2.43 10a 
10b C16H33 3.50 
10c 11-yne 3.96 
17a C12H25 1.79 
17b C6H13 NEa 
a The ATX inhibition assay was performed by Dr. Damian Madan at Echelon Biosciences 
Inc., Utah. 











Table 5.2. Inhibition of 10b in various cell lines.a 
 












Figure 5.5. Reduction of cell migration by 10b in Ovcar-3 cell line. (Scratch wound-
healing assay was carried out by Dr. Mandi Murph’s lab at the University of Georgia. 







Figure 5.6. Reduction of cell migration by 10b in MDA-MB-231 cell line. (Scratch 
wound-healing assay was carried out by Dr. Mandi Murph’s lab at the University of 





5.5 Experimental Procedures 
All chemicals and solvents were purchased from Aldrich, Alfa Aesar or Acros 
Chemical Corporation and used without prior purification. Thin-layer chromatography 
was performed on pre-coated silica gel aluminum sheets (EM SCIENCE silica gel 60F254). 
Purification of compounds was carried out by normal phase chromatography (ISCO 
[Combiflash], Silica gel 230~400 mesh). NMR spectra were recorded using a Varian 
Mercury 400 at 400 MHz (1H), 101 MHz (13C), 162 MHz (31P), 376 MHz (19F) at 25oC. 
Chemical shifts are given in ppm with TMS as internal standard (δ=0.00); 31P, 85% 
H3PO4 (δ=0.00). NMR peaks were assigned by MestRe-C (4.9.9.9). Low resolution mass 
spectra were obtained on HP5971A MSD double focusing mass spectrometer instrument. 
 
5.5.1 General procedure for preparing sulfide 3, 13a, and 13b  
The ethyl 2-bromopropionate (5 g, 36.0 mmol) was dissolved in acetone (200 mL). 
To this, K2CO3 (7.45 g, 54.0 mmol, 1.5 equiv.) was added, followed by methyl-2 
mercaptoacetate (4.2 g, 39.5 mmol, 1.1 equiv.). Then, the reaction mixture was heated at 
reflux for 2 h. After cooling to room temperature, the mixture was filtered out and then 
the white cake was washed by acetone 25 mL X 2. All combined organic solvents were 
evaporated under reduced pressure. The residue was purified on silica column (EtOAc-














1H NMR (CDCl3) δ 3.67 (s, 3H), 3.66 (t, J = 6.0 Hz, 2H), 3.19 (s, 2H), 2.68 (t, J = 
7.2 Hz, 2H), 2.54 (s, 1H), 1.78 (m, 2H); 13C NMR (CDCl3) δ 171.1 (s), 61.0 (s), 52.4 (s), 
33.4 (s), 31.5 (s), 29.2 (s); MS (ESI) m/z 165.2 (M++1). 
 








1H NMR (CDCl3) δ 4.14-4.25 (m, 2H), 3.69 (s, 3H), 3.20-3.26 (m, 1H), 2.81-2.92 
(m, 2H), 2.56-2.64 (m, 2H), 1.81-1.92 (m, 2H), 1.60-1.68 (m, 2H), 1.21-1.48 (m, 21H), 
0.87 (t, J = 6.8 Hz, 3H); 13C NMR (CDCl3) δ 172.7 (s), 172.1 (s), 61.1 (s), 51.7 (s), 46.8 
(s), 34.4 (s), 31.9 (s), 31.4 (s), 29.2-29.6 (m), 27.3 (s), 26.2 (s), 22.7 (s), 14.2 (s), 14.1 (s); 
MS (ESI) m/z 375.4 (M++1). 
 




1H NMR (CDCl3) δ 4.14-4.25 (m, 2H), 3.69 (s, 3H), 3.20-3.26 (m, 1H), 2.80-2.92 
(m, 2H), 2.56-2.64 (m, 2H), 1.81-1.92 (m, 2H), 1.60-1.68 (m, 2H), 1.21-1.48 (m, 9H), 
0.87 (t, J = 6.8 Hz, 3H); 13C NMR (CDCl3) δ 172.7 (s), 172.0 (s), 61.1 (s), 51.7 (s), 46.8 
(s), 34.4 (s), 31.5 (s), 31.3 (s), 28.8 (s), 27.3 (s), 26.2 (s), 22.5 (s), 14.2 (s), 14.0 (s); MS 
(ESI) m/z 291.3 (M++1). 
 










1H NMR (CDCl3) δ 7.41-7.45 (m, 6H), 7.20-7.33 (m, 9H), 3.71 (s, 3H), 3.20 (s, 
2H), 3.16 (t, J = 6.0 Hz, 2H), 2.76 (t, J = 7.2 Hz, 2H), 1.89 (m, 2H); 13C NMR (CDCl3) δ 
171.0 (s), 144.2 (s), 128.6 (s), 127.8 (s), 126.9 (s), 86.5 (s), 62.0 (s), 52.4 (s), 33.4 (s), 
29.7 (d); MS (ESI) m/z 429.3 (M+Na+). 
 
5.5.6 General procedure for preparing vinyl sulfone 5, 15a, and 15b 
The corresponding sulfide 4 (24.2 g, 59.7 mmol, 1 equiv.) was dissolved in 
dichloromethane (300 mL) and m-CPBA (25.7 g, 149 mmol, 2.5 equiv.) was added to 
above mixture at 0 ºC (ice bath). The reaction mixture was allowed to warm up to room 
temperature and stirred for 8 h at room temperature. Volatiles were evaporated under 
reduced pressure. The residue was taken up in EtOAc (200 ml) and washed with 10% 
Na2SO3, saturated NaHCO3, and brine. The organic layer was then dried over anhydrous 
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Na2SO4. The volatiles were evaporated under reduced pressure to yield the crude mixture 
that was purified on silica column (EtOAc-Hex, 0 to 50%) to yield the pure product 5. 
(24.8 g, 56.7 mmol, 95%) 
 
5.5.7 Methyl 2-(3-(trityloxy)propylsulfonyl)acetate (5) 
 
1H NMR (CDCl3) δ 7.41-7.51 (m, 6H), 7.20-7.38 (m, 9H), 3.97 (s, 2H), 3.81 (s, 
3H), 3.38-3.46 (m, 2H), 2.29 (t, J = 5.6 Hz, 2H), 2.05-2.21 (m, 2H); 13C NMR (CDCl3) δ 
163.5 (s), 143.9 (s), 128.6 (s), 128.0 (d), 127.9 (s), 127.2 (s), 86.9 (s), 61.3 (s), 57.2 (s), 
53.4 (s), 51.3 (s), 22.9 (s); MS (ESI) m/z 439.3 (M++H). 
 








1H NMR (CDCl3) δ 3.90-4.05 (m, 2H), 3.79 (t, J = 6.0 Hz, 2H), 3.22 (t, J = 7.6 
Hz, 2H), 2.94-3.02 (m, 1H), 2.49 (s, 2H), 2.06-2.15 (m, 2H), 1.84-1.95 (m, 1H), 1.52-
1.72 (m, 1H), 1.45-1.55 (m, 1H), 1.22-1.40 (m, 19H), 0.88 (t, J = 6.8 Hz, 3H); 13C NMR 
(CDCl3) δ 64.6 (s), 60.6 (s), 59.6 (s), 49.4 (s), 31.4 (s), 29.3-29.6 (m), 26.9 (s), 24.3 (s), 
24.2 (s), 22.5 (s), 14.0 (s); MS (ESI) m/z 337.3 (M++H). 
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1H NMR (CDCl3) δ 3.90-4.05 (m, 2H), 3.75 (t, J = 6.0 Hz, 2H), 3.21 (t, J = 7.6 
Hz, 2H), 2.94-3.02 (m, 1H), 2.82 (s, 2H), 2.03-2.11 (m, 2H), 1.84-1.95 (m, 1H), 1.58-
1.69 (m, 1H), 1.42-1.52 (m, 1H), 1.22-1.40 (m, 7H), 0.86 (t, J = 6.8 Hz, 3H); 13C NMR 
(CDCl3) δ 64.6 (s), 60.6 (s), 59.6 (s), 49.4 (s), 31.4 (s), 29.0 (s), 26.9 (s), 24.3 (s), 24.2 (s), 
22.5 (s), 14.0 (s); MS (ESI) m/z 253.3 (M++H). 
 
5.5.10 General procedure for preparing sulfone 6a and 6b 
To a solution of 3.7 g (6.41 mmol, 1 equiv.) of Methyl 2-(3-
(trityloxy)propylsulfonyl)acetate (5) in 20 mL of DMF was added sodium hydride (60% 
in mineral oil, 400 mg, 9.7 mmol, 1.15 equiv.). Then the reaction mixture was stirred at 
room temperature for 1 h before 3.82 g (10.2 mmol, 1.2 equiv.) oleic iodide in 10 mL 
DMF was added. The mixture was stirred for additional 4 h before 1N HCl (100 mL) was 
added to quench the reaction, and the mixture was extracted with 100 mL of EtOAc twice. 
The combined organic extracts were washed with saturated NaHCO3 solution, followed 
by a saturated NaCl solution. Solvent was removed at reduced pressure and the crude 
mixture was purified on silica column (EtOAc-Hex, 0 to 20%) to give clear oil 6a. (3.18 

















1H NMR (CDCl3) δ 7.41-7.51 (m, 6H), 7.20-7.38 (m, 9H), 5.31-5.39 (m, 2H), 
3.83 (s, 3H), 3.76-3.81 (m, 1H), 3.15-3.32 (m, 4H), 1.99-2.18 (m, 6H), 1.20-1.40 (m, 
26H), 0.90 (t, J = 6.8 Hz, 3H); 13C NMR (CDCl3) δ 167.0 (s), 143.8 (s), 130.0 (s), 129.8 
(s), 128.6 (s), 127.9 (d), 127.1 (s), 86.8 (s), 68.7 (s), 61.5 (s), 53.2 (s), 48.6 (s), 31.9 (s), 
29.1-29.8 (m), 27.2 (m), 26.2 (s), 22.7 (s), 22.1 (s), 14.2 (s); MS (ESI) m/z 711.6 
(M+Na+). 
 












1H NMR (CDCl3) δ 7.40-7.51 (m, 6H), 7.21-7.39 (m, 9H), 3.81 (s, 3H), 3.76-3.81 
(m, 1H), 3.21-3.46 (m, 4H), 2.14-2.23 (m, 4H), 1.60-1.67 (m, 2H), 1.20-1.40 (m, 26H), 
0.88 (t, J = 6.8 Hz, 3H); 13C NMR (CDCl3) δ 167.0 (s), 143.8 (s), 128.6 (s), 127.8 (d), 
127.1 (s), 86.8 (s), 68.7 (s), 61.5 (s), 53.2 (s), 48.6 (s), 31.9 (s), 29.1-29.8 (m), 27.2 (m), 




5.5.13 General procedure for preparing 7a, 7b and 7c 
To an ice-cooled solution of 800 mg (1.16 mmol, 1 equiv.) of 6a in 15 mL of 
tetrahedronfuran, 44 mg (1.16 mmol, 1.0 equiv.) of lithium aluminium hydride was added. 
Then the reaction mixture was stirred at 0 oC for 10 min. Then 20 mL water was added to 
quench the reaction, and the mixture was extracted with 50 mL of EtOAc X 2. The 
combined organic extracts were washed with 1N HCl, saturated NaHCO3 solution, 
followed by a saturated NaCl solution. Solvent was removed at reduced pressure and the 
crude mixture was purified on silica column (EtOAc-Hex, 5 to 25%) to give the product 
7a (390 mg, 0.59 mmol, 51%). 
 











1H NMR (CDCl3) δ 7.41-7.51 (m, 6H), 7.20-7.38 (m, 9H), 5.31-5.39 (m, 2H), 
3.93-4.06 (m, 2H), 3.24 (t, J = 6.0 Hz, 2H), 3.11-3.17 (m, 2H), 2.92-3.00 (m, 1H), 2.57 (t, 
J = 6.0 Hz, 2H), 2.16-2.20 (m, 2H), 1.95-2.04 (m, 4H), 1.82-1.92 (m, 1H), 1.61-1.71 (m, 
1H), 1.45-1.54 (m, 1H), 1.20-1.40 (m, 22H), 0.88 (t, J = 6.8 Hz, 3H); 13C NMR (CDCl3) 
δ 143.8 (s), 130.0 (s), 129.8 (s), 128.5 (s), 127.9 (s), 127.1 (s), 86.8 (s), 63.8 (s), 61.5 (s), 
59.5 (s), 49.5 (s), 31.9 (s), 29.1-29.8 (m), 27.2 (d), 26.9 (s), 24.3 (s), 22.7 (s), 22.3 (s), 
















1H NMR (CDCl3) δ 7.40-7.51 (m, 6H), 7.21-7.38 (m, 9H), 3.93-4.06 (m, 2H), 
3.24 (t, J = 6.0 Hz, 2H), 3.11-3.17 (m, 2H), 2.92-3.00 (m, 2H), 2.57 (t, J = 6.0 Hz, 2H), 
2.16-2.20 (m, 2H), 1.82-1.92 (m, 1H), 1.61-1.71 (m, 1H), 1.20-1.40 (m, 26H), 0.89 (t, J = 
6.8 Hz, 3H); 13C NMR (CDCl3) δ 143.8 (s), 128.5 (s), 127.9 (s), 127.1 (s), 86.8 (s), 63.8 
(s), 61.5 (s), 59.5 (s), 49.5 (s), 31.9 (s), 29.1-29.8 (m), 27.2 (d), 26.9 (s), 24.3 (s), 22.7 (s), 
22.3 (s), 14.1 (s); MS (ESI) m/z 657.5 (M+Na+). 
 










1H NMR (CDCl3) δ 7.41-7.51 (m, 6H), 7.20-7.38 (m, 9H), 3.93-4.06 (m, 2H), 
3.24 (t, J = 6.0 Hz, 2H), 3.11-3.17 (m, 2H), 2.57 (t, J = 6.0 Hz, 2H), 2.16-2.20 (m, 2H), 
2.08-2.16 (m, 2H), 1.84-1.96 (m, 2H), 1.62-1.72 (m, 1H), 1.46-1.56 (m, 3H), 1.20-1.40 
(m, 11H); 13C NMR (CDCl3) δ 143.8 (s), 128.5 (s), 127.9 (s), 127.1 (s), 86.8 (s), 84.7 (s), 
68.1 (s), 63.9 (s), 61.5 (s), 59.5 (s), 49.6 (s), 29.4 (s), 29.3 (s), 29.2 (s), 29.0 (s), 28.7 (s), 




5.5.17 General procedure for removing trityl group to  
give 8a, 8b and 8c 
To a solution of 330 mg (0.6 mmol, 1 equiv.) of 7a in 5 mL of dichloromethane, 
0.4 mL of TFA was added. Then the reaction mixture was stirred at room temperature for 
30 min. 30 mL saturated NaHCO3 solution was added to quench the reaction, and the 
mixture was extracted with EtOAc (50 mL) X 3. The combined organic solvent was 
removed at reduced pressure and the crude mixture was purified on silica column 
(EtOAc-Hex, 50 to 100%) to give the product 8a (203 mg, 0.49 mmol, 81%). 
 








1H NMR (CDCl3) δ 5.31-5.39 (m, 2H), 3.93-4.06 (m, 2H), 3.81 (t, J = 6.0 Hz, 2H), 
3.22 (t, J = 7.2 Hz, 2H), 2.95-3.03 (m, 1H), 2.07-2.17 (m, 2H), 1.88-2.12 (m, 6H), 1.61-
1.71 (m, 1H), 1.45-1.54 (m, 1H), 1.20-1.40 (m, 24H), 0.88 (t, J = 6.8 Hz, 3H); 13C NMR 
(CDCl3) δ 130.0 (s), 129.8 (s), 64.5 (s), 60.7 (s), 59.6 (s), 49.0 (s), 31.9 (s), 29.1-29.8 (m), 
27.2 (d), 26.9 (s), 24.3 (s), 22.7 (s), 14.1 (s); MS (ESI) m/z 419.4 (M++1). 
 









1H NMR (CDCl3) δ 3.93-4.06 (m, 2H), 3.80 (t, J = 6.0 Hz, 2H), 3.21 (t, J = 7.6 
Hz, 2H), 2.95-3.03 (m, 1H), 2.07-2.17 (m, 2H), 1.88-2.12 (m, 2H), 1.61-1.71 (m, 1H), 
1.45-1.54 (m, 1H), 1.20-1.40 (m, 26H), 0.88 (t, J = 6.8 Hz, 3H); 13C NMR (CDCl3) δ 
64.5 (s), 60.7 (s), 59.6 (s), 49.0 (s), 31.9 (s), 29.1-29.8 (m), 27.2 (d), 26.9 (s), 24.3 (s), 
22.7 (s), 14.1 (s); MS (ESI) m/z 361.4 (M++1). 
 
5.5.20 2-(3-Hydroxypropylsulfonyl)tridec-12-yn-1-ol (8c) 
 
1H NMR (CDCl3) δ 3.93-4.06 (m, 2H), 3.76 (t, J = 6.0 Hz, 2H), 3.21 (t, J = 7.6 
Hz, 2H), 2.94-3.02 (m, 1H), 2.84 (s, 1H), 2.16-2.20 (m, 2H), 2.08-2.16 (m, 2H), 1.84-
1.96 (m, 2H), 1.62-1.72 (m, 1H), 1.46-1.56 (m, 3H), 1.20-1.40 (m, 12H); 13C NMR 
(CDCl3) δ 84.7 (s), 68.1 (s), 64.6 (s), 60.6 (s), 59.6 (s), 49.4 (s), 29.4 (s), 29.3 (s), 29.2 (s), 
29.0 (s), 28.7 (s), 28.4 (s), 27.0 (s), 24.3 (s), 24.1 (s), 18.4 (s); MS (ESI) m/z 341.1 
(M+Na+). 
 
5.5.21 General procedure for preparing 9a, 9b, 9c, 16a and 16b 
To a solution of 2.0 g (7.92 mmol, 1 equiv.) of 15b and diisopropylethylamine 
(5.1g, 39.4 mmol, 5 equiv.) in 40 mL of dichloromethane, mesyl chloride (2.74 g, 19.0 
mmol, 2.4 equiv.) was added dropwise. Then the reaction mixture was stirred at room 
temperature for 2 h. The mixture was filtered out. The filtrate was washed by saturated 
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NaHCO3 solution and then dried over sodium sulfate. The organic solvent was 
concentrated and the residue was dissolved into acetone (30 mL) followed by NaI (3.6 g, 
16 mmol, 3 equiv.) and NaHCO3 (1.0 g, 11.9 mmol, 2.2 equiv.). The reaction mixture 
was stirred at room temperature for overnight, filtered out and concentrated. 50 mL water 
and 50 mL EtOAc was added to the residue. Then the organic layer was collected. The 
water layer was washed by EtOAc X 2. The combined organic solvent was dried over 
sodium sulfate and then removed at reduced pressure. 100 mL EtOAc was added 
followed by adding diisopropylethylamine (5 mL). The reaction mixture was stirred at 
room temperature for 3 days. The organic solvent was removed at reduced pressure and 
the crude mixture was purified on silica column (EtOAc-Hex, 0 to 15%) to give the 
product 16b (2.5 g, 7.26 mmol, 92%). 
 
5.5.22 (Z)-2-(3-Iodopropylsulfonyl)icosa-1,11-diene (9a) 
 
1H NMR (CDCl3) δ 6.25 (s, 1H), 5.83 (s, 1H), 5.31-5.40 (m, 2H), 3.28 (t, J = 6.4 
Hz, 2H), 3.07 (t, J = 7.6 Hz, 2H), 2.41 (t, J = 7.6 Hz, 2H), 2.22-2.30 (m, 2H), 1.94-2.06 
(m, 4H), 1.56-1.66 (m, 2H), 1.20-1.40 (m, 22H), 0.88 (t, J = 6.8 Hz, 3H); 13C NMR 
(CDCl3) δ 146.0 (s), 126.9 (s), 126.6 (s), 122.0 (s), 64.5 (s), 49.7 (s), 28.8 (s), 26.1-26.6 





5.5.23 2-(3-Iodopropylsulfonyl)octadec-1-ene (9b) 
 
1H NMR (CDCl3) δ 6.18 (s, 1H), 5.77 (s, 1H), 3.22 (t, J = 6.4 Hz, 2H), 3.02 (m, 
2H), 2.34 (t, J = 7.6 Hz, 2H), 2.14-2.23 (m, 2H), 1.50-1.58 (m, 2H), 1.56-1.66 (m, 2H), 
1.20-1.40 (m, 24H), 0.81 (t, J = 6.8 Hz, 3H); 13C NMR (CDCl3) δ 145.6 (s), 122.0 (s), 
49.5 (s), 28.7 (s), 26.0-26.4 (m), 25.8 (s), 24.4 (s), 22.9 (d), 19.5 (s), 10.9 (s); MS (ESI) 
m/z 507.3 (M+Na+). 
 
5.5.24 2-(3-Iodopropylsulfonyl)tridec-1-en-12-yne (9c) 
 
1H NMR (CDCl3) δ 6.25 (s, 1H), 5.83 (s, 1H), 3.29 (t, J = 6.4 Hz, 2H), 3.05-3.10 
(m, 2H), 2.40 (t, J = 7.6 Hz, 2H), 2.22-2.29 (m, 2H), 2.16-2.20 (dt, J = 6.8, 2.8 Hz, 2H), 
1.94 (t, J = 6.8 Hz, 1H), 1.48-1.65 (m, 4H), 1.20-1.40 (m, 10H); 13C NMR (CDCl3) δ 
145.7 (s), 122.0 (s), 81.5 (s), 64.9 (s), 49.6 (s), 26.4 (s), 26.1 (s), 26.0 (s), 25.8 (d), 25.5 






5.5.26 2-(3-Iodopropylsulfonyl)tetradec-1-ene (16a) 
 
1H NMR (CDCl3) δ 6.23 (s, 1H), 5.81 (s, 1H), 3.28 (t, J = 6.4 Hz, 2H), 3.07 (t, J = 
7.6 Hz, 2H), 2.40 (t, J = 7.6 Hz, 2H), 2.21-2.30 (m, 2H), 1.52-1.63 (m, 2H), 1.25-1.42 (m, 
18H), 0.87 (t, J = 6.8 Hz, 3H); 13C NMR (CDCl3) δ 145.9 (s), 122.0 (s), 49.7 (s), 28.7 (s), 
26.1-26.6 (m), 25.9 (s), 24.6 (s), 23.0 (s), 19.5 (s), 11.0 (s); MS (ESI) m/z 451.3 (M+Na+). 
 
5.5.27 2-(3-Iodopropylsulfonyl)oct-1-ene (16b) 
 
1H NMR (CDCl3) δ 6.25 (s, 1H), 5.83 (s, 1H), 3.28 (t, J = 6.8 Hz, 2H), 3.08 (t, J = 
7.6 Hz, 2H), 2.41 (t, J = 7.6 Hz, 2H), 2.21-2.30 (m, 2H), 1.52-1.63 (m, 2H), 1.25-1.42 (m, 
6H), 0.89 (t, J = 6.8 Hz, 3H); 13C NMR (CDCl3) δ 145.9 (s), 122.0 (s), 49.7 (s), 28.3 (s), 
26.6 (s), 25.6 (s), 24.6 (s), 23.1 (s), 19.4 (s), 10.9 (s); MS (ESI) m/z 367.2 (M+Na+). 
 
5.5.28 General procedure for preparing 10a, 10b, 10c, 17a and 17b 
To a solution of 81 mg (0.16 mmol, 1 equiv.) of 9a in 5 mL/1 mL of 
ethanol/dichloromethane, trimethylamine in ethanol was added. Then the reaction 
mixture was stirred at room temperature for 4 days. The resulting mixture was 
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concentrated and then dissolved into ethanol (0.5 mL) followed by adding diethyl ether 
(10 mL). The white solid was crashed out then the mixture was filtered out. The white 
solid was collected to give the final product, which passed through chloride ion exchange 
resin to convert to HCl salt 10a (51 mg, 0.11 mmol, 71%). 
 
5.5.29 (Z)-3-(Eicosa-1,11-dien-2-ylsulfonyl)-N,N,N-trimethylpropan 
-1-ammonium chloride (10a) 
 
1H NMR (CDCl3) δ 6.26 (s, 1H), 5.88 (s, 1H), 5.85 (s, 1H), 5.31-5.40 (m, 2H), 
3.98-4.40 (m, 2H), 3.59 (s, 3H), 3.45 (s, 9H), 3.18 (t, J = 6.8 Hz, 2H), 2.84 (d, J = 6.8 Hz, 
2H), 2.34-2.43 (m, 4H), 1.57-1.62 (m, 2H), 1.32-1.42 (m, 22H), 0.87 (t, J = 6.8 Hz, 3H); 
13C NMR (CDCl3) δ 149.1 (s), 130.0 (s), 129.7 (s), 125.6 (s), 64.5 (s), 53.7 (s), 52.0 (s), 
48.6 (s), 44.9 (s), 31.9 (s), 29.0-29.7 (m), 27.7 (s), 27.2 (d), 22.6 (d), 16.5 (s), 14.1 (s); 
MS (ESI) m/z 442.5 (M+). 
 
5.5.30 N,N,N-Trimethyl-3-(octadec-1-en-2-ylsulfonyl)propan 




1H NMR (CD3OD) δ 6.25 (s, 1H), 5.98 (s, 1H), 3.48-4.55 (m, 2H), 3.26 (s, 2H), 
3.16-3.22 (m, 11H), 2.45 (t, J = 7.6 Hz, 2H), 2.18-2.28 (m, 2H), 1.60-1.67 (m, 2H), 1.32-
1.42 (m, 24H), 0.90 (t, J = 6.8 Hz, 3H); 13C NMR (CD3OD) δ 149.2 (s), 125.1 (s), 64.3 
(s), 52.2 (m), 48.4 (s), 31.7 (s), 29.0-29.4 (m), 28.8 (s), 27.6 (s), 22.3 (d), 16.2 (s), 13.0 
(s); MS (ESI) m/z 416.5 (M+). 
 
5.5.31 N,N,N-Trimethyl-3-(tridec-1-en-12-yn-2-ylsulfonyl)propan 
-1-ammonium chloride (10c) 
 
1H NMR (CD3OD) δ 6.25 (s, 1H), 5.98 (s, 1H), 3.48-3.56 (m, 2H), 3.16-3.22 (m, 
11H), 2.45 (t, J = 7.6 Hz, 2H), 2.20-2.28 (m, 2H), 2.13-2.20 (m, 3H), 1.60-1.68 (m, 2H), 
1.46-1.54 (m, 2H), 1.20-1.40 (m, 10H); 13C NMR (CD3OD) δ 149.1 (s), 125.1 (s), 83.6 
(s), 68.0 (s), 52.2 (m), 29.2 (s), 29.1 (s), 29.0 (s), 28.7 (s), 28.3 (d), 27.6 (s), 17.6 (s), 16.3 
(s); MS (ESI) m/z 342.3 (M+). 
 
5.5.32 N,N,N-Trimethyl-3-(tetradec-1-en-2-ylsulfonyl)propan 




1H NMR (CD3OD) δ 6.25 (s, 1H), 5.98 (s, 1H), 3.48-3.56 (m, 2H), 3.27 (s, 2H), 
3.16-3.22 (m, 11H), 2.45 (t, J = 7.6 Hz, 2H), 2.20-2.28 (m, 2H), 1.60-1.66 (m, 2H), 1.26-
1.44 (m, 16H), 0.90  (t, J = 6.8 Hz, 3H); 13C NMR (CD3OD) δ 149.2 (s), 125.1 (s), 64.3 
(s), 52.2 (m), 31.4 (s), 28.8-29.3 (m), 27.7 (s), 26.7 (s), 22.3 (s), 16.2 (s), 13.0 (s); MS 
(ESI) m/z 360.3 (M+). 
 
5.5.33 N,N,N-Trimethyl-3-(oct-1-en-2-ylsulfonyl)propan 
-1-ammonium chloride (17b) 
 
1H NMR (CDCl3) δ 6.28 (s, 1H), 5.88 (s, 1H), 4.05-4.13 (m, 2H), 3.43 (s, 9H), 
3.22 (t, J = 6.8 Hz, 2H), 2.38-2.46 (m, 4H), 1.55-1.65 (m, 2H), 1.28-1.42 (m, 6H), 0.89 (t, 
J = 6.8 Hz, 3H); 13C NMR (CDCl3) δ 149.1 (s), 125.8 (s), 54.1 (s), 48.3 (s), 31.5 (s), 29.6 
(s), 28.6 (s), 27.7 (s), 22.5 (s), 16.6 (s), 14.0 (s); MS (ESI) m/z 276.4 (M+). 
 
5.5.34 General procedure for preparing diol 13a, 13b 
To an ice-cooled solution of 3.8 g (13.1 mmol, 1 equiv.) 12a in 100 mL of 
tetrahedronfuran, 2.0 g (52.6 mmol, 4.0 equiv.) of lithium aluminum hydride was added. 
The reaction mixture was stirred at 0 oC for 10 min. Then the reaction temperature was 
allowed to raise to 60 oC overnight. The reaction mixture was cooled down to room 
temperature and filtered out. The organic solvent was concentrated before 100 mL EtOAc 
was added. The organic layer was washed with 1N HCl, saturated NaHCO3 solution, 
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followed by a saturated NaCl solution. Solvent was removed at reduced pressure and the 
crude mixture was purified on silica column (EtOAc-Hex, 25 to 50%) to give the product 
14a (2.6 g, 11.8 mmol, 90%). 
 







1H NMR (CDCl3) δ 3.76 (t, J = 6.0 Hz, 2H), 3.55-3.60 (m, 1H), 3.46-3.52 (m, 1H), 
2.58-2.76 (m, 3H), 2.00 (s, 2H), 1.81-1.89 (m, 2H), 1.45-1.62 (m, 3H), 1.21-1.44 (m, 
19H), 0.88 (t, J = 6.8 Hz, 3H); 13C NMR (CDCl3) δ 63.9 (s), 61.5 (s), 49.6 (s), 32.4 (s), 
31.9 (s), 31.8 (s), 29.3-29.6 (m), 27.1 (s), 26.7 (s), 22.7 (s), 14.1 (s); MS (ESI) m/z 327.3 
(M+Na+). 
 







1H NMR (CDCl3) δ 3.76 (t, J = 6.0 Hz, 2H), 3.46-3.52 (m, 1H), 2.58-2.76 (m, 3H), 
2.03 (s, 2H), 1.81-1.89 (m, 2H), 1.45-1.62 (m, 3H), 1.21-1.44 (m, 8H), 0.88 (t, J = 6.8 Hz, 
3H); 13C NMR (CDCl3) δ 63.9 (s), 61.5 (s), 49.6 (s), 32.4 (s), 31.8 (s), 31.7 (s), 29.1 (s), 
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LPA exerts cell proliferation, morphological changes, and has been studied to be 
involved in multiple physiological and pathological response including, angiogenesis, 
myelination, neurogenesis, wound healing, tumorigenesis and cancer-related 
inflammation through activation of these GPCRs.1-5 To elucidate the molecular 
mechanism of ATX-LPA receptor axis actions and develop new therapeutic reagents for 
the treatment of cancer and other diseases,6 I synthesized a set of molecules with either 
LPA receptor agonistic/antagonistic or ATX inhibitory activities accordingly. 
 In Chapter 2, phosphonothioate analogue (thio-ccPA 18:1) of carbacyclic 
phosphatidic acid (ccPA) was previously prepared by chemical synthesis, which inhibited 
Ca2+ release through LPA1/LPA3 activation and was an LPA1/LPA3 antagonist. To 
support in vivo study, a scalable synthetic method was developed. This compound was 
selected to test the potential as melanoma therapeutic in vitro and as a probe of relative 
efficacy of inhibition of ATX, LPA1 and LPA3. The study revealed that thio-ccPA 18:1 
induced a marked reduction in the viability of B16F10 metastatic melanoma cells 
compared with PBS-treated control by 80-100% by Dr. Murph at the University of 
Georgia.  
 In Chapter 3, S32826 is a phosphonate analogue that is the first nanomolar 
inhibitor of ATX. S32826 features a tridecylamide substituent on an aromatic ring, and 
its poor solubility and bioavailability severely limits its utility in vivo. cLogP calculations 
revealed the lipophilicity of S32826 could be lowered by shortening its hydrophobic 
chain and by introducing substituents alpha to the phosphonate. Herein, we described the 
syntheses and structure-activity relationships of a set of α-substituted phosphonate 
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analogues of S32826 and their inhibition of ATX in vitro in Chapter 3. Dr. Aoki at 
Tohuku University further examined the use of these analogues to reduce migration of 
A549 lung carcinoma and MB-231 breast cancer cell lines in vitro.  
Chapter 4 described an efficient method for the synthesis of metabolically 
stabilized sn-2 radyl phosphorothioate analogues of lysophosphatidic acid (LPA). The 
pharmacological properties of these analogues were characterized for subtype-specific 
LPAR agonist activity using AP-TGFα release assay in HEK293 cells. Compared to 1-
oleoyl-2-O-methyl-glycerophosphothioate (sn-1 OMPT) analogues previously prepared, 
sn-2 radyl OMPT analogues showed similar agonist activity for LPA3/P2Y5. Most 
importantly, sn-2 alkyl OMPT analogues are the very potent LPA5 agonists. The 
availability of new sn-2 radyl OPMT analogues expands the scope of structure-activity 
studies and will further refine the molecular nature of ligand-receptor interactions for this 
class of GPCRs. 
In Chapter 5, fluorophosphonate and vinyl sulfone analogues of LPC were 
designed to serve as ABP to identify ATX from other NPP members. The study revealed 
that fluorophosphonate displayed low shelf-life, and was hydrolyzed rapidly. Vinyl 
sulfone analogues of LPC showed irreversible kinetics. However, the further evidence is 
needed to fully support irreversible inhibition. Dr. Madan at Echelon Bioscienes 
demonstrated vinyl sulfone analogues of LPC showed good inhibition of ATX in vitro. 
Dr. Murph at the University of Georgia further examined the use of these analogues to 
reduce migration of OVCAR-3 human ovarian carcinoma and MDA-MB-231 breast 




6.2 Future Perspectives 
6.2.1 Perspective A 
Although the S32826 analogues we made displayed significant improvement of 
solubility, they are still not good enough for the drug candidates. I will discuss some 
future possible modifications on this series. First of all, the hydrophobic chain in the 
S32826 analogues is one of major reasons for the low solubility and bioavailability. As 
we know, the long hydrophobic chain not only decreases the solubility of molecules but 
also increase the chance of drug molecule binding with membrane, which will reduce the 
bioavailability significantly. Hence, regarding to the future optimization of these 
analogues, the nonlipid substituted analogues should be synthesized to improve 
bioavailability. Secondly, following Dr. Stamford’s suggestion that phosphonic acid in 
S32826 analogues is another reason for the low solubility, using the bioisosteric 
functional groups such as carboxylic acid to replace phosphonic acid will be the possible 
next generation of ATX inhibitors. The pro-drug strategy, which has been showed 
successful application in drug design, is another possible way to improve the solubility as 
well. I propose that the ready-to-cleave phosphonate instead of phosphonic acid will 
improve the solubility and bioavailability dramatically.    
 
6.2.2 Perspective B  
 The sn-2 radyl phosphorothioate analogues of LPA we synthesized in Chapter 4 
are the most potent LPA5 agonists, which is a good starting point for the future studies. 
However, before we synthesized these analogues, we did not know which enantiomer 
will be potent; the racemic starting material was used at the beginning. It is necessary to 
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synthesize the pure enantiomer of all sn-2 radyl phosphorothioate analogues of LPA. In 
addition, sn-2 radyl phosphonothioate analogues of LPA may show better potency 
because they are resistant to the hydrolysis by the enzyme. Meanwhile, the SAR between 
the chain length and potency also is interesting point for the future study. 
 
6.2.3 Perspective C 
As we discussed previously, fluorophosphonate and vinyl sulfone of LPC 
analogues failed to serve as ABP for selected enzymes of NPP family. The reason for 
failure of fluorophosphonate is because of its high reactivity; and the difficulty of 
performing click chemisty is maybe the reason why we cannot detect the inhibitor-ATX 
adduct. The advantage of using alkyne as the reporting group in this thesis is that small 
alkyne could help ABP approach the active site of enzyme in vivo. Regard to the further 
experiment to design new ABP, the direct built-in fluorescent group attached on the vinyl 
sulfone to serve as the tag which is easy to detect on SDS-PAGE should be synthesized. 
The newly designed analogues may serve as ABP of NPP family in vitro, even with a 
bulky reporting group. 
 
6.3 Conclusion 
In conclusion, a set of LPAR agonists, antagonists and ATX inhibitors have been 
synthesized in this dissertation. Further pharmacological studies on these compounds I 
made elucidate the SAR profile of LPA and lead the way to synthesize more potent and 
stable LPA analogues or nonlipid molecules with desired pharmacological properties. 
LPA and its metabolic pathway have been identified play very important roles in 
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mediating growth and motility of cancer cells. Development of novel reagents targeting 
LPARs and its metabolic pathway has broad application in drug discovery. It is worth 
noting that several groups have made their efforts to synthesize a number of non-lipid 
ATX inhibitors.7-9 The modification based on these small molecules combined with 
S32826 analogues we developed is important future research direction, which can result 
in the development of a clinically useful drug. 
Encouragingly, both big pharmaceutical firms and startup companies have 
involved in the discovery of new drug candidates targeting LPARs and its metabolic 
pathway. (Figure 6.1) Amgen reported a number of LPA2 antagonists and some key 
compound, for example the compound showed in Figure 6.1, was evaluated in vitro for 
inhibition of LPA2 mediated Erk activation and proliferation of HCT-116 colon cancer 
cells.10 Bleomycin used as antibiotic was pulled out from the market due to its severe side 
effect, which induced pulmonary fibrosis. The mice treated with LPA1 receptor 
antagonist-AM966, which was developed by Amira Pharmaceuticals Inc., showed 
dramatic protection from the bleomycin-induced lung fibrosis.11 Most recently, Pfizer 
disclosed its potent ATX inhibitor-PF8380, which showed very good anti-inflammatory 
properties.9 All above exciting progress suggest the potential for the treatment of cancers 
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